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Abstract  
Granulosa Cell Tumor (GCT) is a hormonally active and highly vascularized subtype of 
ovarian cancer, constituting 5% of all ovarian malignancies. GCTs are characterized by an 
indolent, albeit often unpredictable, course of disease, with a 5-year survival rate of over 
90%. Recurrences occur in 20-30% of GCT patients, even in early-stage disease, and 
sometimes unexpectedly late after the primary tumor.  Initial tumor stage is the only 
prognostic factor in GCTs, and molecular prognostic factors are lacking. Further, the 
treatment of advanced or recurrent GCT is difficult, leading to increased mortality and 
underscoring the need for biologically targeted treatments for aggressive GCTs. 
 
GCTs are thought to arise from the proliferating granulosa cells of preovulatory follicles. 
The molecular mechanisms leading to GCT formation are likely to include regulators of 
granulosa cell proliferation and apoptosis; however, the pathogenesis of GCTs remains 
unknown. We studied regulators of granulosa cell function and tumor angiogenesis in 
GCT pathogenesis by utilizing tumor tissue and patient serum samples and cell culture 
assays. The objectives of this study were to find new molecular prognostic factors and to 
identify targets for new biological treatments for GCT. 
  
Anti-Müllerian Hormone (AMH) is a crucial regulator of granulosa cell function that 
belongs to the large transforming growth factor-β (TGF-β) family of growth factors. GCTs 
express AMH and knockout mouse models targeting TGF-β/AMH signaling suggest that 
AMH acts as a growth inhibitor in GCT pathogenesis. We found that GCTs expressed the 
AMH receptors, with the AMH type II receptor (AMHRII) being characteristic of GCTs. 
AMH expression was decreased in large GCTs, and recombinant AMH inhibited growth 
of GCT cells in vitro. The results support the premise that AMH acts as a growth inhibitor 
in GCTs, and AMH and AMHRII emerge as targets for treatment of GCT.  
 
Vascular Endothelial Growth Factor-A (VEGF) is a key factor in tumor angiogenesis and 
also regulation of granulosa cell proliferation and function in the ovary. VEGF has been 
successfully targeted in the treatment of several forms of cancer. We found that VEGF and 
its functional receptor VEGFR-2 are highly expressed in GCTs; VEGFR-2 was also 
expressed in the active, phosphorylated form. GCTs produced significant amounts of 
VEGF that could also be detected in the serum of GCT patients.  In cell culture assays, the 
inhibition of VEGF by soluble anti-VEGF antibody (bevacizumab) inhibited growth and 
induced apoptosis of GCT cells. These results indicate an auto- or paracrine pro-
tumorigenic role of VEGF in GCTs and encourage targeting VEGF and VEGFR-2 in the 
treatment of aggressive GCTs. 
 
In search of new molecular prognostic factors, we utilized a tumor tissue microarray of 80 
primary GCT patients. Transcription factor GATA4 was previously found to be associated 
with GCT pathogenesis and to delineate an aggressive subset of GCTs. Epidermal Growth 
Factor Receptors (EGFR/HERs) are regulators of normal granulosa cell function and 
overexpressed in many cancer types. HER2 is a known oncogene and a target for 
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 2 
treatment in breast and gastric cancer. The roles of HERs in GCT prognosis have thus far 
been unknown. We found, in contrast to previous studies, that initial tumor stage was not 
prognostic of tumor recurrence, and up to 20% of the stage Ia GCTs recurred. High 
expression of both GATA4 and HER2, and high nuclear atypia were prognostic of tumor 
recurrence, also in early-stage tumors. In multivariate analyses of molecular prognostic 
factors, GATA4 was superior to HER2, and high GATA4 expression led to a 4-fold 
increase in recurrence risk. GATA4 expression was also prognostic of shorter disease-
specific survival along with higher tumor stage (II-III) and nuclear atypia. These results 
suggest that GATA4 could be used in prognostic assessment of GCTs, especially in early-
stage GCTs.  
 
Taken together, these studies have provided novel insight into the pathogenesis of GCTs 
and will potentially improve the prognostic evaluation and the development of biological 
treatment options for GCT patients. 
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Abbreviations 
AHR adjusted hazard ratio 
ALK activin receptor-like kinase 
AMH anti-Müllerian hormone  
AMHRII anti-Müllerian hormone 
 receptor II 
Bcl2 B-cell lymphoma-2 
BMP bone morphogenic protein 
BrdU  bromodeoxyuridine 
BVZ bevacizumab 
cDNA complementary DNA 
DAPI 4´,6-diamino-2-phenylindole 
 hydrochloride 
DFS disease-free survival 
DSS disease-specific survival 
ECM extracellular matrix 
EGF epidermal growth factor 
ELISA enzyme-linked 
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FCS fetal calf serum 
FFCS female fetal calf serum 
FOG-2 friend of GATA-2 
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FSH follicle-stimulating hormone 
GATA4 GATA binding protein 4 
GCT granulosa cell tumor 
GDF growth and differentiation 
 factor 
Her heregulin 
HIF-1α hypoxia-inducible factor 1α 
HR hazard ratio 
IHC immunohistochemistry 
kDa kilo Dalton 
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mRNA messenger RNA 
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ng nanograms 
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pVEGFR-2 phosphorylated VEGFR-2 
rhAMH recombinant human AMH 
SE standard error 
SF-1 steroidogenic factor-1 
TGF-β transforming growth factor-β 
TRAIL tumor necrosis factor-related 
 apoptosis-inducing ligand 
TTMA tumor tissue microarray 
VEGF vascular endothelial growth 
 factor-A 
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VEGFR-2  VEGF receptor-2 
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Introduction 
Ovarian cancer is the fifth most common cancer in women, and, despite recent 
developments in diagnostics and treatments, the leading cause of death from gynecological 
cancer worldwide. Granulosa cell tumor (GCT) is the second most common subtype of 
ovarian cancer, representing 5% of all ovarian malignancies. GCTs are hormonally active 
and highly vascularized tumors that are characterized by an indolent course of disease, 
with a 5-year survival rate of over 90%. However, recurrences occur in 20-30% of 
patients, also those with early-stage disease, leading to higher mortality. The pathogenesis 
and factors affecting prognosis of GCTs are largely unknown.  
 
GCTs are thought to arise from the rapidly proliferating granulosa cells of preovulatory 
follicles. During folliculogenesis granulosa cells proliferate and interact through endocrine 
and paracrine mechanisms to prepare the oocyte for fertilization. Initially, several 
primordial follicles are recruited to enter the rapid growth phase in which the granulosa 
cells proliferate. This phase is dependent on autocrine and paracrine actions of 
intraovarian factors and proceeds independently of pituitary gonadotropins. After one of 
the follicles is cyclically selected, the growth of the dominant follicle becomes dependent 
on gonadotropins and proceeds to ovulation and subsequent corpus luteum formation. The 
remaining secondary follicles undergo atresia, and the granulosa cells die of programmed 
cell death, i.e. apoptosis. The balance between granulosa cell proliferation and apoptosis is 
strictly controlled by several autocrine and paracrine growth factors such as follicle-
stimulating hormone (FSH), anti-Müllerian hormone (AMH), and transforming growth 
factor-β (TGF-β). 
 
Growth factors are naturally occurring proteins that act via a paracrine mechanism to 
promote cellular growth, proliferation, and differentiation. Growth factors bind to their 
specific receptors commonly located on the surface of the target cells. The binding of the 
growth factor to its receptor initiates a strictly controlled cascade of intracellular signals 
that are mediated through phosphorylation of specific amino acid residues on the 
receptors, signaling molecules and protein kinases. The target of these events is the 
activation of transcription factors, proteins that bind specific sites of DNA to initiate 
transcription of DNA to mRNA, leading to altered protein synthesis. This strictly 
controlled activation or inactivation of transcription factors determines cell-specific gene 
expression and protein synthesis, leading to altered cellular proliferation and 
differentiation. 
 
It is commonly known that tumor formation occurs due to genetic changes that lead to 
growth advantage and the transformation of normal cells into malignant cells. This 
involves misregulation of cell proliferation and apoptosis, which are likely to be 
fundamental processes in GCT pathogenesis. This study focuses on investigating the 
expression and function of granulosa cell growth and transcription factors in GCT 
pathogenesis. The purpose of this study was to find new target molecules for prognostic 
evaluation and for the development of new treatment options for GCT patients. 
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Finnish summary 
Munasarjasyöpä on toiseksi yleisin gynekologinen syöpä, joka hoitojen kehityksestä 
huolimatta aiheuttaa merkittävää kuolleisuutta. Granuloosasolukasvain (GSK) on 
munasarjasyövän alatyyppi, jonka ennuste on useimmiten hyvä. Kasvain kuitenkin uusii 
20-30%:lla potilaista, ja kuolleisuus uusiutuneeseen tautiin on korkea. GSK:n 
tautimekanismit ja ennustetekijät ovat pääosin tuntemattomia, eikä sen hoitoon ole 
käytössä kohdennettuja biologisia hoitomuotoja.  
 
GSK:n ajatellaan saavan alkunsa munasarjan granuloosasoluja säätelevien tekijöiden 
häiriöistä. Tässä tutkimuksessa selvitettiin granuloosasolujen kasvutekijöiden ja 
verisuonikasvutekijän roolia GSK:n syntymekanismeissa. Tutkimuksen tavoitteena oli 
selvittää uusia kohdemolekyylejä GSK potilaiden hoidon kehittämiseen sekä osoittaa 
uusia ennustetekijöitä potilaiden ennusteen arvioimiseen. Työssä käytettiin kudos- ja 
seeruminäytteitä, sekä solumalleja. 
 
Anti-Müllerian hormoni (AMH) on tärkeä granuloosasolujen säätelijähormoni. 
Tutkimustulosten mukaan AMH ilmentyi voimakkaasti pienissä GSK:ssa ja esti lisäksi 
kasvainsolujen kasvua osoittaen AMH:n toimivan kasvunrajoitetekijänä GSK:ssa. GSK:t 
ilmensivät vahvasti myös AMH:n reseptori II:ta, joka on mahdollinen kohde uusille 
syöpähoidoille.  
 
Verisuonikasvutekijä VEGF on tärkeä kasvainten verisuonistusta säätelevä tekijä, ja tärkeä 
kohde jo käytössä oleville syöpähoidoille. Tutkimuksen mukaan GSK:t ilmensivät 
vahvasti VEGF:ää ja sen reseptoreita. GSK solut tuottivat VEGF:ää ja se oli merkitsevästi 
koholla myös GSK potilaiden seerumissa. Solutöissä pystyimme aiheuttamaan GSK 
solujen kuoleman VEGF vasta-aineella (bevasitsumabi). Tulokset viittaavat VEGF:än 
toimivan kasvaimen kasvua edistävänä tekijänä, ja osoittavat VEGF-kohdennetun hoidon 
olevan vaihtoehto myös GSK:ten hoidossa. 
 
GATA4 on tärkeä granuloosasolujen geeninsäätelijä, joka on tämän tutkimuksen tulosten 
mukaan uusi itsenäinen ennustetekijä GSK:ssa. Vahvaan GATA4:n ilmentymiseen liittyi 
nelinkertainen riski taudin uusiutumiselle sekä kohonnut riski myös tautispesifiselle 
kuolemalle. HER2 on tunnettu syöpägeeni ja munasarjan toiminnan säätelijä, jota vastaan 
on käytössä kohdennettuja syöpähoitoja. Tutkimustulosten mukaan HER2:n vahva 
ilmentyminen ennusti GSK:n aggressiivista käyttäytymistä. HER2 on siten mahdollinen 
kohde biologisille syöpähoidoille myös GSK:ssa.  
 
Tässä tutkimuksessa tunnistettiin uusia molekyylejä, jotka osallistuvat GSK:n syntyyn. 
Näitä molekyylejä voidaan käyttää biologisten hoitojen kehittämiseen GSK potilaille. 
Tutkimuksessa löytyi myös kaksi uutta ennustetekijää GSK:n uusiutumiselle, joista 
GATA4:ää voidaan käyttää itsenäisenä tekijänä GSK potilaan ennusteen arvioimisessa.  
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Review of the literature 
Ovarian cancer is classified into three groups based on histopathological patterns that 
reflect the various cell types present in the ovary; epithelial ovarian tumors, sex cord 
stromal tumors, and germ cell tumors (Ries 2007). The majority (80-90%) of ovarian 
cancers are derived from the surface epithelium of the ovary: the epithelial ovarian tumors. 
Sex cord stromal tumors arise from the sex cord and stromal components and represent 
8% of all ovarian tumors. Germ cell tumors are derived from the primordial germ cells of 
the embryonic gonad. Granulosa cell tumors (GCTs) are the predominant form of sex cord 
stromal tumors, representing 90% of this subgroup. Other subtypes of sex cord stromal 
tumors include thecoma-fibromas, Sertoli-Leydig cell tumors, gynandroblastomas, and sex 
cord tumor with annular tubules.  
1. Granulosa cell tumors 
GCTs are hormonally active ovarian neoplasms characterized by a long natural history and 
overall a favorable prognosis (reviewed in (Schumer 2003) and (Jamieson 2012)). GCTs 
are divided into two distinct subtypes based on histology and clinical characteristics: 
juvenile and adult GCT. Juvenile GCT (JGCT) comprises only 5% of all GCTs (Young 
1984a). JGCT is generally diagnosed in children and adolescents, with a median age at 
diagnosis of 7-8 years (Calaminus 1997). The predominant presenting symptoms in JGCT 
are abdominal pain and endocrine manifestations, commonly precocious pseudopuberty. 
Juvenile GCT typically presents at an early stage and the prognosis is favorable, although 
at advanced stages the clinical course may be more aggressive (Young 1984a; Powell 
1993; Calaminus 1997; Merras-Salmio 2002). Although extremely uncommon, the 
juvenile type can be found in adults and the adult type in children. 
  
Adult GCT (hereafter referred to as GCT) comprises 95% of all GCTs and is the subject 
of this study. The incidence of GCT has generally been reported to be between 0.58 and 
1.6/100 000 (Stenwig 1979; Bjorkholm 1981; Ohel 1983); in Finland, the incidence was 
reported to be 0.47/100 000 (Unkila-Kallio 1998). No specific risk factors are known for 
the development of GCT; menopausal status and parity (Evans 1980; Young 1984b; 
Malmstrom 1994) or the use of fertility drugs (Unkila-Kallio 2000) or oral contraceptives 
("The reduction in risk of ovarian cancer associated with oral-contraceptive use."  1987) 
are not associated with the risk of GCT. Further, the risk of GCT is not associated with 
germline mutations of BRCA1 or BRCA2, unlike epithelial ovarian cancer (Koul 2000). 
1.1 Clinical presentation and diagnosis  
GCTs most commonly present during the perimenopausal or early postmenopausal period, 
with a median age at diagnosis between 50 and 54 years (Schumer 2003). At diagnosis, 
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 8 
the tumor is usually confined to one ovary, but may be large with a mean tumor diameter 
of 9-12 cm (Malmstrom 1994; Nosov 2009; Sun 2012). The vast majority (70-90%) of 
GCTs are diagnosed at Stage I (Malmstrom 1994; Auranen 2007; Ayhan 2009; Sun 2012) 
(Table 1).  
Table 1. Staging of ovarian cancer according to the International Federation of 
Gynecology and Obstetrics (FIGO 2009) 
 
 
The most commonly presenting symptoms are abnormal uterine bleeding caused by the 
excess estrogen production by the tumor, and abdominal symptoms caused by a large 
pelvic mass. In premenopausal patients, GCTs may cause menstrual irregularities, 
menorrhagia, amenorrhea, and infertility (Unkila-Kallio 2000; Ayhan 2009; Sun 2012). In 
older women, postmenopausal bleeding is the most common symptom (Evans 1980; Ohel 
1983; Cronje 1998). The tumor-produced estradiol may result in endometrial hyperplasia 
or even endometrial adenocarcinoma in 5-10% of patients (Fox 1975; Stenwig 1979; 
Evans 1980; Unkila-Kallio 2000; Auranen 2007). In addition, patients with GCT are at 
increased risk of breast cancer, with a reported incidence of 3.7-20% (Ohel 1983). GCTs 
are also highly vascularized and may present with acute abdominal pain and 
hemoperitoneum caused by tumor rupture (Fox 1975; Stenwig 1979; "Case records of the 
Massachusetts General Hospital." 1995;  Poma 1998). 
  
The gross appearance of a GCT is commonly a solid and cystic tumor mass in which the 
cyst may contain hemorrhagic fluid (Young 1992). At histological examination, GCT 
reveals a distinctive appearance (Figure 1 A), containing round to oval, pale cells with 
characteristic coffee bean grooved nuclei (Figure 1 B, arrowheads) and scarce cytoplasm. 
GCT presents with a variety of histological patterns, including both well-, and poorly 
differentiated histologies. The well-differentiated forms are further subdivided into 
microfollicular, marofollicular, trabecular, insular, and tubular patterns (Young 1992) 
based on their appearance. The poorly differentiated forms are characterized by a diffuse 
(sarcomatoid) pattern and monotonous cellular growth (Figure 1 A). The histological 
diagnosis of GCT can be challenging, and especially the sarcomatoid subtype can be 
I 
   Ia 
   Ib 
   
   Ic 
The tumor is confined to the ovary/ovaries 
Tumor is in one ovary and the ovary capsule is intact. No malignant cells in the abdominal cavity. 
Tumor is in both ovaries but the ovary capsule is intact. No malignant cells in the abdominal 
cavity. 
The tumor is limited to one or both ovaries. The ovary capsule is ruptured, tumor reaches the 
ovary surface, or malignant cells are detected in the abdominal cavity. 
II The tumor involves one or both ovaries and has extended to the pelvis. 
III The tumor involves one or both ovaries with microscopically confirmed peritoneal 
metastases outside the pelvis and/or regional lymph node metastasis. Includes liver capsule 
metastases. 
IV Distant metastasis beyond the peritoneal cavity, and liver parenchymal metastasis. 
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mistaken for a poorly differentiated carcinoma on intraoperative frozen section. Detailed 
analysis and immunohistochemistry (IHC) for inhibin-α and cytokeratin are recommended 
in clinical pathology for confirmation of GCT diagnosis (Hildebrandt 1997; Cathro 2005; 
Nofech-Mozes 2012). In retrospective studies utilizing GCT tissue samples, histological 
re-evaluation of adult GCTs is evermore critical since the mis-diagnosis rates can be as 
high as 53% (Cronje 1999). Unlike carcinomas, GCTs usually present mild nuclear atypia 
and few mitotic figures (Young 1992). 
 
Figure 1. Histological appearance of GCT with hematoxylin staining. Appearance of a 
typical diffuse (sarcomatoid) subtype of GCT, arrows indicate blood vessels with 
lumen (A). Coffee bean-like grooved nuclei (arrowheads) in B. Scale bars: 100 µm 
in A and 50 µm in B. 
1.2 Treatment and follow-up  
Surgery is the primary treatment option for GCT; the extent of surgery can be modified 
according to age and need to preserve fertility. The recommended form of surgery is total 
abdominal hysterectomy and bilateral salpingo-oophorectomy (SO), including staging 
procedures (Stuart 2003; Colombo 2007; Pectasides 2008). However, in stage Ia patients, 
unilateral SO appears to be an accepted course of action, especially in younger patients 
wishing to preserve fertility (Bjorkholm 1981; Zhang 2007; Lee 2008). The role of 
surgical staging is not as evident as in epithelial ovarian cancer, but at least peritoneal 
cytology is recommended (Stuart 2003). Occasionally peritoneal/para-aortic lymph node 
dissection, omentectomy, and peritoneal biopsies are performed (Schumer 2003), although 
the prognostic significance of these staging factors is not well defined (Lee 2008; 
Fotopoulou 2010; Thrall 2011). Adjuvant therapy is recommended only in advanced 
stages or recurrent disease (Stuart 2003).  
 
The surgical treatment of recurrent GCTs is often challenging (Fotopoulou 2010), and 
patients commonly experience several relapses and are thus subjected to multiple 
operations and treatment modalities (Auranen 2007; Lee 2008). Most recurrences are 
REVIEW OF THE LITERATURE 
 
 
 
 
 10 
intra-abdominal, and hepatic metastasis is rather common (Auranen 2007; Lee 2008; 
Fotopoulou 2010), whereas lymphatic or distant metastasis is rarely seen. No standard 
guidelines exist for the treatment of recurrent GCT; however, it is commonly agreed that 
the removal of recurrent mass should be performed, and recurred GCT patients show good 
survival after optimal cytoreduction with or without adjuvant chemotherapy (Al-Badawi 
2002). Data on the efficacy of adjuvant therapies are limited due to lack of prospective 
randomized studies, and the current literature consists of case reports and small 
retrospective reviews of patient files (Auranen 2007). Chemotherapy treatment consists of 
platinum-based combination treatments, showing response rates of 60-90% (Homesley 
1999; Pautier 2008). Radiotherapy and hormonal treatment (GnRH antagonists, 
tamoxifen, and aromatase inhibitors) are sometimes used (Kauppila 1992; Freeman 2006), 
although the long-term effects of these modalities remain unknown. The limited effects of 
current non-surgical treatments underscore the need for new biologically targeted 
treatments for advanced or recurred GCT patients. 
 
In Finland, the follow-up of GCT patients has traditionally been similar to that of 
epithelial ovarian cancer patients, consisting of clinical controls at 3- to 12-month 
intervals over 5 years. After 3-5 years, hospital controls cease and patients are referred to a 
general physician or a private gynecologist. The clinical control comprises a physical 
examination combined with a pelvic ultrasound and blood tests/serum markers. X-ray or 
CT scans are used only with suspicion of recurrence. Inhibin B is the serum marker 
currently used in GCT patient follow-up, but it has certain limitations. Serum inhibin B 
levels can be elevated also in other ovarian tumors, especially in mucinous ovarian cancers 
(Robertson 2007), and inhibin B levels fluctuate during the menstrual cycle leading to 
false-positive results in premenopausal women. Further, normal inhibin B levels do not 
rule out ovarian malignancy (Mom 2007). 
1.3 Survival and prognostic factors  
In contrast to epithelial ovarian cancer, GCT is considered to be of low malignant 
potential and is characterized by a slow and indolent growth with a tendency towards late 
recurrence. The 5-year survival rates of stage I patients ranges from 75% to 95%, being 
over 90% in most series (Schumer 2003; Colombo 2007), and the 10-year survival is 84-
95% (Schwartz 1976; Pankratz 1978). In stage II-IV patients, the survival rates are lower; 
5-year survival ranges from 22% to 75% (Stenwig 1979; Bjorkholm 1981; Fujimoto 
2001), and 10-year survival is 17-65% (Schwartz 1976; Pankratz 1978). The recurrence 
rates have varied from 10% to 30% in previous studies (Malmstrom 1994; Cronje 1998; 
Ayhan 2009; Nosov 2009), being around 20-25% in larger series with longer follow-up 
periods (Lee 2008; Sun 2012). The mean time to first recurrence has been reported to be 
4-8 years (Evans 1980; Malmstrom 1994; Lee 2008; Sun 2012). However, Cronje et al. 
reported 17% of the recurrences to take place after 10 years (Cronje 1999), and 
recurrences 30-40 years after the diagnosis have been described (Hines 1996; East 2005). 
With recurrence, the mortality rises to 60-80% (Fox 1975; Cronje 1999). 
REVIEW OF THE LITERATURE 
 
 
 
 
 11 
 
Tumor stage at the time of diagnosis is the only factor explicitly related to survival (Miller 
1997; Fujimoto 2001; Zhang 2007; Lee 2008; Miller 2008; Ayhan 2009; Sun 2012). Other 
prognostic factors have been difficult to establish, most likely due to the relative rarity of 
the disease and the long follow-up period required to include all potentially recurrent 
tumors. Rupture of the tumor capsule has been implicated as an adverse prognostic 
indicator, also in stage I GCT (Bjorkholm 1981; Costa 1996; Auranen 2007). Some 
studies have reported postoperative residual tumor to be a negative prognostic factor, as 
expected (Bjorkholm 1981; Costa 1996; Sehouli 2004; Auranen 2007; Lee 2008).  
 
Large tumor size has been shown to be an adverse prognostic factor in several studies 
(Stenwig 1979; Bjorkholm 1981; Chan 2005; Ranganath 2008; Sun 2012), with critical 
sizes varying from 5 to 25 cm. However, the adjustment of tumor stage is not clearly 
defined in these studies. Further, many other studies have not found tumor size to be of 
prognostic significance (Malmstrom 1994; Cronje 1999; Anttonen 2005; Auranen 2007; 
Lee 2008; Nosov 2009).  
 
Data on age at diagnosis as a prognostic factor are conflicting. Some authors describe an 
association between older age and poor prognosis (Stenwig 1979; Ohel 1983; Costa 1996), 
while others have noted that younger age is associated with a poor prognosis (Pankratz 
1978; Nosov 2009). Further, no association of patient age with prognosis was found in 
other studies (Evans 1980; Miller 1997). Parity and reproductive status do not seem to 
influence outcome in GCTs (Fox 1975; Evans 1980). 
 
Many studies have assessed the value of mitotic activity and nuclear atypia in GCTs, but 
again the data are conflicting. Some studies have found high mitotic activity to predict 
worse prognosis (Bjorkholm 1981; Malmstrom 1994; Fujimoto 2001; Miller 2001; 
Sehouli 2004), while others have contradicted this finding (Costa 1996; Anttonen 2005; 
Villella 2007; Leuverink 2008). Nuclear atypia has been shown to be associated with 
aggressive behavior in GCTs by some (Stenwig 1979; Bjorkholm 1981; Ohel 1983; Miller 
1997), but not all authors (Kim 2006; Villella 2007). Disparities in these data are probably 
attributable to the highly subjective assessment of the degrees of mitotic activity and 
nuclear atypia, and the varying methodologies used. Many other factors related to cell 
proliferation or DNA integrity, such as Ki67, p53, and DNA aneuploidy, show conflicting 
data regarding prognosis (King 1996; Auranen 2007; Miller 2008; Pectasides 2008). The 
different histological subgroups are not associated with prognosis (Auranen 2007). 
Furthermore, a few other molecular markers have been investigated for prognostic 
significance, including members of the epidermal growth factor receptor (EGFR) family, 
tumor suppressor protein p53, and tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) receptors (King 1996; Juric 2001; Nosov 2009; Kyronlahti 2010). Molecular 
prognostic factors are, however, still lacking, and the search is ongoing. Transcription 
factor GATA4 was reported to be associated with aggressive GCTs also after adjusting for 
tumor stage (Anttonen 2005), and GATA4 is thus far the most promising prognostic 
marker for GCT.  
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All in all, initial tumor stage remains the only solid prognostic factor in GCTs. However, 
the majority of GCT patients being diagnosed at stage I emphasizes the need for new 
molecular prognostic factors that are able to predict tumor recurrence. Moreover, 
molecular prognostic markers are required to identify the high-risk patients who would 
benefit from adjuvant treatment and an extended follow-up. 
2. Pathogenesis 
2.1 GCT pathogenesis 
GCT cells exhibit many characteristics of proliferating granulosa cells of preovulatory 
follicles, including the production of estrogen and inhibin (Lappohn 1989; Amsterdam 
1997; Lague 2008), expression of the FSH receptor (Fuller 1998), and GATA4 expression 
(Laitinen 2000; Anttonen 2005). The pathogenesis of GCTs remains largely unknown, but 
the molecular changes are likely to involve disruption of the signaling pathways that 
regulate granulosa cell proliferation and apoptosis.  
2.1.1 FOXL2 mutation 
Cytogenetic studies have shown that GCTs exhibit a relatively stable karyotype compared 
with other ovarian cancers (Lin 2005; Mayr 2008). Recent developments in highly 
efficient genomic analyses have allowed more detailed analysis of GCTs. Using whole-
transcriptome RNA sequencing technology, Shah et al. identified a single somatic 
missense mutation in transcription factor FOXL2 (402C-G) in four GCTs (Shah 2009). 
The predicted consequence at the protein level was the substitution of a tryptophan residue 
for a highly conserved cysteine residue (C134W). Direct DNA sequencing revealed that 
the mutation was present in 97% of adult GCTs, as later confirmed by our group 
(Jamieson 2010) and others (Kim 2010a; Kim 2010b; Al-Agha 2011; Gershon 2011; Hes 
2011). The lack of this mutation in juvenile GCTs, other sex cord stromal tumors, or other 
tumor types suggests that it is pathognomonic to adult GCT (Shah 2009; Jamieson 2010; 
Al-Agha 2011; Gershon 2011).  
 
FOXL2 is a forkhead transcription factor that plays a crucial role in regulating follicular 
development in the normal ovary (Schmidt 2004; Uda 2004), and it is abundantly 
expressed in the granulosa cells of preovulatory follicles (Moumne 2008). During 
embryonic development FOXL2 regulates ovarian and granulosa cell differentiation 
(Schmidt 2004). In GCTs, the functional role of FOXL2 mutation is unraveled, but 
functional analyses suggest that FOXL2 acts as a tumor suppressor in normal granulosa 
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cells and that the C134W mutation impairs FOXL2’s ability to mediate apoptosis (Lee 
2005; Kim 2011). 
2.2 AMH and TGF-β signaling pathway 
Anti-Müllerian Hormone (AMH), also known as Müllerian Inhibiting Substance (MIS), is 
a 140 kilo Dalton (kDa) dimeric glycoprotein that belongs to the large transforming 
growth factor-β (TGF-β) growth factor family. During embryonic development AMH is 
expressed solely in the Sertoli cells of the male, causing the embryonic regression of the 
Müllerian ducts, the precursors of the uterus, fallopian tubes and upper vagina (Lee 1993). 
In the male, Sertoli cells produce AMH during fetal development, and the testes continue 
the production throughout life, regulating Leydig cell steroidogenesis (Josso 2006). In the 
female, the sex-dimorphic pattern is lost postnatally and AMH is also expressed in 
granulosa cells of the ovary (Visser 2005). The biological effects of AMH are mediated 
through a transmembrane serine/threonine kinase type II receptor (AMHRII) that is 
specifically expressed in the gonads and in mesenchymal cells adjacent to the Müllerian 
ducts. In the adult female, AMHRII is expressed in granulosa cells and at low levels in 
ovarian stroma and endometrium (Bakkum-Gamez 2008; Song 2009). Low levels of 
AMHRII are also present in non-gynecological tissues, including liver parenchyma, 
kidney tubules, breast ducts, exocrine pancreas, and bronchiolar epithelium (Bakkum-
Gamez 2008). In gynecological cancers, AMRII is highly expressed in cancers of the 
ovary, endometrium, cervix, and breast (Masiakos 1999; Ha 2000; Renaud 2005; 
Bakkum-Gamez 2008; Song 2009). 
2.2.1 AMH expression and function in the ovary 
AMH expression is undetectable in the fetal ovary and weak in the postnatal ovary, but 
after puberty its expression starts in the granulosa cells of small preantral follicles (Figure 
2) (Visser 2005; Broekmans 2008). The expression is highest in granulosa cells of large 
preantral and small antral follicles, and diminishes in the next stages of follicle 
development. AMH is no longer expressed during the final stages of follicle growth, and 
AMH expression also disappears in atretic follicles. In granulosa cells, AMH expression is 
regulated by steroidogenic factor-1 (SF-1), GATA4 (Tremblay 1999; Anttonen 2003), and 
FSH (Taieb 2011). The granulosa cell-produced AMH regulates follicular development by 
inhibiting the initial recruitment of primordial follicles (Visser 2006). FSH is the 
gonadotrophin that stimulates antral follicle growth, and AMH regulates the cyclic 
recruitment of follicles by decreasing the responsiveness of small antral follicles to FSH 
(Visser 2006).  
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Figure 2. Role of AMH in folliculogenesis. The oocytes are shown in black, granulosa cell 
layers in gray and follicular fluid in white. AMH is produced predominantly in the 
small antral follicles; the thickness of the gray arrows represents the relative 
amount of AMH production. AMH inhibits the initial recruitment and FSH-
dependent cyclic recruitment. Modified from Broekmans 2008. 
The actions of AMH in the adult ovary are autocrine and paracrine in nature, but the 
release of AMH from granulosa cells leads to measurable serum levels, which are 
proportional to the number of developing follicles in the ovaries. The recent development 
of highly sensitive, standardized ELISA to evaluate serum AMH has raised interest in 
clinical applications (Streuli 2009). Serum AMH is a unique marker in the evaluation of 
ovarian function, especially when considering the reproductive capacity in women 
(reviewed in (Broekmans 2008; Visser 2012)).   
2.2.2 AMH signaling: the TGF-β/BMP- pathway 
AMH belongs to the large TGF-β superfamily of highly conserved but functionally 
diverse groups of growth factors involved in numerous physiological processes during 
pre- and postnatal life (Massague 2000a). In vertebrates, there are at least 35 ligands in the 
TGF-β superfamily that signal through seven transmembrane receptors. The different 
TGF-β superfamily ligands can form active signaling complexes by binding to one or 
more combinations of the receptors in the TGF-β/bone morphogenic protein (BMP) 
pathway, allowing cell-specific responses (Massague 2000b). 
 
The complex regulation of the TGF-β/BMP pathway relies on the phosphorylation of 
different downstream effectors (Smads) by specific ligand-receptor binding (reviewed in 
(Schmierer 2007)). The ligands comprise TGF-β-type ligands (TGF-β, activin, and nodal) 
as well as BMP-type ligands (AMH, BMP, and growth and differentiation factors 
(GDFs)). The receptors of this pathway are classified into type I (activin receptor-like 
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kinases, ALKs) and type II receptors that form heterodimers upon ligand binding (Figure 
3). Downstream of the receptors the signal is conveyed by the Smads, which are 
transcription factors that transmit the signaling to the nucleus and regulate gene 
expression. Different Smads are activated by different ligands; TGF-β, activin, and nodal 
activate Smad2/3, and AMH, BMPs, and GDFs Smad1/5/8. Also the type I receptors are 
divided based on different Smad activation; ALK4, ALK5, and ALK7 activate Smad2/3, 
and ALK1, ALK2, ALK3, and ALK6 activate Smad1/5/8. 
 
 
Figure 3. TGF-β/BMP signaling pathway. Upon ligand binding, type I and type II receptors 
form heterodimers, autophosphorylate and subsequently phosphorylate specific 
downstream Smads. The activated Smads form a transcription complex with a co-
Smad (Smad4), which then enters the nucleus and binds specific sites of DNA to 
control gene transcription. Modified from Schmierer 2007.  
2.2.3 TGF-β signaling and AMH in GCT tumorigenesis  
Imbalances in TGF-β/BMP signaling are likely to contribute to GCT pathogenesis, and 
several mouse models suggest that overactivity of TGF-β-type signaling and Smad2/3 
contributes to GCT formation. Matzuk et al. first reported this phenomenon in α-inhibin-
deficient mice that developed sex cord stromal tumors of granulosa cell origin through 
overactive activin/TGF-β signaling (Matzuk 1992). The mechanism was further elaborated 
when the downstream Smad3 was additionally deleted and the tumor formation was 
delayed in these mice (Li 2007a; Li 2007b).  Moreover, in mice lacking Smad1/5 in 
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granulosa cells the overactivity of Smad 2/3 resulted in the formation of aggressive GCTs 
(Pangas 2008; Middlebrook 2009); however, these tumors resembled more the juvenile 
GCTs. In addition, GCTs developed in mice when the BMP type I receptors ALK3 and 
ALK6 were deleted from granulosa cells (Edson 2010). These findings suggest that the 
BMP/AMH-type pathway acts as a tumor suppressor in normal granulosa cells.  
 
Previous studies have shown that AMH is expressed in GCTs (Ragin 1992; Rey 2000; 
Anttonen 2005). However, in large human and mouse GCTs, AMH tissue expression 
levels are reduced (Dutertre 2001; Anttonen 2005). AMHRII is expressed in human GCTs 
at higher levels than in other ovarian cancer types (Salhi 2004; Song 2009), and AMHRII 
has been shown to be functional and to activate Smad1 upon AMH stimulation in murine 
GCTs (Dutertre 2001). Moreover, AMH has been suggested as a therapeutic agent in 
AMHRII-expressing human cancers; AMH inhibits the growth of AMHRII-positive 
cancer cells in vitro (Masiakos 1999; Ha 2000) and in vivo (Stephen 2002). This growth 
inhibition is mediated through AMHRII and results in a block in cell cycle progression, 
with subsequent apoptosis (Masiakos 1999; Ha 2000). The functional role of AMHRII in 
GCTs remains obscure.  
 
GCTs express high levels of AMH in the tissues, and high levels of AMH can also be 
detected in the serum of GCT patients (Rey 2000). Previous studies suggest that AMH is a 
serum marker for GCT (Long 2000; Rey 2000). Serum AMH has also been reported to 
positively correlate with tumor size (Chang 2009). The clinical use of AMH has thus far 
been discouraged because of the lack of studies describing the value of AMH in a larger 
pool of GCT patients. A comparative study with the current marker inhibin B in a single 
patient cohort is needed to validate the clinical use of AMH in GCT patients (Streuli 
2009).  
2.3 Tumor angiogenesis: VEGF and endostatin  
Tumor growth relies on mechanisms of angiogenesis - the growth of new blood vessels 
from pre-existing vasculature - to supply oxygen and nutrients. The angiogenic process is 
driven by growth factors of which Vascular Endothelial Growth Factor-A (VEGF) seems 
to be the most important in tumors (reviewed in (Ferrara 2004)). VEGF is a 21 kDa 
protein originally found to induce proliferation, sprouting, migration, and tube formation 
of vascular endothelial cells (reviewed in (Ferrara 2003)). During embryogenesis VEGF is 
required for hematopoiesis, vasculogenesis, and angiogenesis and Vegf knockout is 
embryonic lethal (Ferrara 2003). During embryonic development VEGF plays a crucial 
role in organ growth and development. In the adult, VEGF is expressed during neo-
angiogenesis; in the ovary and endometrium during the menstrual cycle, in wound healing, 
and in tumors (reviewed in (Tammela 2005)). At least six VEGF isoforms of variable 
amino acid number are produced through alternative splicing; VEGF121, VEGF165, and 
VEGF189 are the major forms produced by most cell types (Robinson 2001) (Figure 4). 
The different isoforms differ in the heparin-binding domain, resulting in various 
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extracellular matrix (ECM) binding properties (Ferrara 2003); VEGF121 is a freely 
diffusible protein, VEGF189 is almost completely bound to the ECM, and VEGF165 has 
intermediate properties. The ECM binding forms a biological regulatory mechanism that 
allows the ECM bound isoforms to be released in a diffusible form by plasmin cleavage. 
In addition, VEGF165, but not VEGF121, interacts with coreceptors, such as the neuropilins, 
to enhance VEGFR-2 signaling (Soker 2002). 
  
Figure 4. The three major VEGF isoforms are formed as a result of alternative mRNA 
splicing and differ by their ECM binding properties.  The proteins are depicted 
from N to C terminus and the exons are numbered below the bar. Binding sites for 
VEGFR-1 and VEGFR-2 are marked with black stripes and the plasmin cleavage 
site with an arrow. Modified from Robinson 2001.  
 
 
 
 
 
 
 
 
 
 
 
VEGF binds to two tyrosine kinase receptors, VEGFR-1 (Fms-like kinase-1, Flt-1) and 
VEGFR-2 (Fetal liver kinase-1 (Flk-1) or kinase-insert domain receptor (KDR)), 
expressed primarily in endothelial cells (Ferrara 2003) (Figure 5). VEGFR-1 and VEGFR-
2 are also expressed in osteoblasts, inflammatory cells, and hematopoietic stem cells. 
VEGFR-1 expression is upregulated during angiogenesis and in hypoxia, unlike VEGFR-2 
(Gerber 1997). The expression of VEGFR-2 is autoregulated; VEGF upregulates its 
expression (Shima 1995). Both VEGF receptors are essential for embryonic vasculature 
formation and hematopoiesis, and knockout mice are embryonic lethal (Shalaby 1997), 
although mice lacking only the intracellular tyrosine kinase part of VEGFR-1 are viable 
and have only slightly impaired angiogenesis in adults (Hiratsuka 1998).  
 
The tyrosine kinase receptors consist of an extracellular ligand-binding domain, a single 
transmembrane region, and an intracellular domain with intrinsic protein kinase activity. 
The tyrosine kinase receptors typically form hetero- or homodimers upon activation. The 
binding of VEGF to its receptor causes the autophosphorylation of specific intracellular 
tyrosine residues, which in turn initiates multiple signaling cascades that utilize, for 
instance, the mapkinase, protein-kinase C, and protein-kinase B pathways to induce 
endothelial cell survival, proliferation, angiogenesis, and vasopermeability. Although 
VEGF binds to VEGF-R1 and -2 with similar affinity, the phosphorylation of VEGF-R1 is 
weak, and VEGF-R2 is thus considered the main mediator of VEGF function (Tammela 
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2005). Furthermore, VEGF-R1 also exists in a soluble extracellular form, which may act 
as regulator of VEGF function, and is associated with pathological conditions such as 
preeclampsia and ovarian hyperstimulation syndrome (Tammela 2005; Pau 2006). 
Figure 5. Summary of VEGF signaling in tumorigenesis. VEGF is produced as a 21 kDa 
protein that is subsequently glycosylated and forms a 45 kDa homodimer. VEGF 
is secreted by the tumor in response to hypoxia, growth factors, and cytokines. The 
VEGF receptors, usually expressed on blood endothelial cells, are composed of 
seven immunoglobulin-like extracellular domains (spheres), and an intracellular 
tyrosine kinase domain (ovals). After VEGF binding to VEGFR-2, the intracellular 
tyrosine residues of VEGFR-20 intrinsically phosphorylate, leading to an 
angiogenic response in endothelial cells. VEGFR-1 activation leads to recruitment 
of endothelial progenitor cells (EPCs). VEGFR-1 is also found as a soluble form 
(sVEGFR-1) that acts as a decoy receptor and binds VEGF. Bevacizumab (BVZ), 
a humanized monoclonal antibody used in cancer therapy, binds soluble VEGF 
and inhibits its binding to the VEGFRs. Modified from Tammela 2004 and 
Ferrara 2003. 
REVIEW OF THE LITERATURE 
 
 
 
 
 19 
2.3.1 VEGF expression and signaling in the ovary 
VEGF plays a crucial role in regulating female reproductive function (Lam 2005). In the 
human ovary, VEGF is crucial for follicular angiogenesis and the development and 
maintenance of the corpus luteum (Geva 2000), and its expression is regulated by 
gonadotrophins (Mattioli 2001). In preovulatory follicles, VEGF is mainly expressed in 
the interstitial tissue and theca layers, whereas in ovulatory and post-ovulatory follicles 
VEGF is abundantly expressed in granulosa and granulosa-lutein cells (Geva 2000; 
Balasch 2004).  
 
Granulosa cells express VEGF (Balasch 2004; Rolaki 2007), and its expression parallels 
follicular angiogenesis; VEGF expression increases with increasing follicle size, is highest 
during ovulation, and gradually diminishes in the developed corpus luteum (Geva 2000; 
Greenaway 2004). VEGF expression also disappears in atretic follicles (Greenaway 2004). 
In granulosa cells, VEGF expression is upregulated by estradiol, progesterone, FSH, and 
luteinizing hormone (LH) (Shimizu 2007). During follicular development VEGF is crucial 
for granulosa cell survival by inhibiting apoptosis (Greenaway 2004; Shin 2006; Kosaka 
2007). Further, VEGF inhibition with a soluble decoy receptor suppresses granulosa cell 
proliferation, follicular development (Wulff 2002), and granulosa cell function (i.e. AMH 
expression) (Thomas 2007). These survival and function-promoting signals seem to be 
mediated by VEGFR-2 (Greenaway 2004). 
  
VEGFR-1 and VEGFR-2 are expressed in granulosa cells (Otani 1999; Greenaway 2004; 
Shimizu 2007) and more intensively in the granulosa-lutein cells of the corpus luteum 
(Otani 1999; Sugino 2000). The expression of VEGFR-2 colocalizes with VEGF 
expression, suggesting an auto-regulatory loop in granulosa cells (Greenaway 2004).  
2.3.2 VEGF in tumors and anti-VEGF cancer treatments 
In growing tumors, hypoxia is the main stimulator of VEGF expression through hypoxia-
inducible factor 1α (HIF-1α), but also many cytokines and growth factors, such as TGF-α 
and TGF-β, insulin-like growth factor-1, and interleukins 1 and 6, stimulate VEGF 
expression (Ferrara 2003). The VEGF secreted by the tumor binds to VEGFR-2 expressed 
in the endothelial cells of adjacent blood vessels, initiating neo-angiogenesis to supply 
oxygen and nutrients to the tumor (Figure 5). VEGF is expressed in the majority of solid 
tumors, and also in some hematological malignancies, and its expression correlates with 
disease progression and survival (Ferrara 2002; Ferrara 2003). Serum VEGF is also 
frequently elevated in the serum of cancer patients, and the levels correlate negatively with 
prognosis in, for example, breast (Salven 1999), prostate (Jones 2000), lung (Salven 
1998), and colorectal cancers (Takeda 2000).  
 
In ovarian cancer, both tumor tissue and serum VEGF expressions correlate negatively 
with prognosis (Yamamoto 1997; Cooper 2002; Li 2004). Small series report VEGF tissue 
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expression also in GCTs (Juric 2001; Li 2004; Schmidt 2008). However, the association of 
VEGF expression with prognosis in GCTs remains to be elucidated. Moreover, serum 
VEGF levels or the expression of VEGF receptors in GCTs have not been characterized 
prior to this study. 
 
Bevacizumab (BVZ) is a humanized monoclonal antibody that binds soluble VEGF and 
inhibits its function (Figure 5). BVZ was approved as an anti-cancer drug by the U.S. 
Food and Drug Administration in 2004 and has been successfully used in the treatment of 
breast, lung, colorectal, and renal cancers (Jubb 2010), and in epithelial ovarian cancer 
(Penson 2010; Perren 2011). Clinical responses of BVZ have been reported also in some 
GCT patients (Kesterson 2008; Tao 2009), and a phase II clinical trial on BVZ in sex cord 
stromal tumors is ongoing (www.clinicaltrials.gov). In ovarian cancer, the clinical 
responses have not been as long-standing as anticipated, and the treatment has caused 
severe adverse effects such as bowel perforation (Burger 2011; Tanyi 2011). New cancer 
drugs targeting the VEGF receptors are being developed and extensively studied in 
clinical trials, with promising anti-tumor activity and hopefully less toxicity (Teoh 2012).  
2.3.3 Endostatin  
Endostatin, a 20 kDa C-terminal fragment of collagen XVIII, is an endogenous inhibitor 
of endothelial cell proliferation and angiogenesis (O'Reilly 1997; Folkman 2006). 
Endostatin inhibits tumor angiogenesis by both downregulating the pro-angiogenic 
factors, including VEGF and VEGFR-2, and upregulating anti-angiogenic factors, such as 
thrombospondin (Abdollahi 2004). Endostatin also induces endothelial cell apoptosis by 
downregulating the anti-apoptotic B-cell lymphoma-2 (Bcl-2) (Dhanabal 1999). 
 
Elevated serum endostatin levels have been reported in various cancers, including those of 
the breast (Zhao 2004), kidney (Feldman 2000), and lung (Suzuki 2002). The exact source 
of circulating endostatin is still unknown, but it is thought to be released from the ECM of 
blood vessel walls and basement membranes by certain proteases, particularly in the liver 
(Schuppan 1998). Endostatin has been a candidate for antiangiogenic cancer therapy 
(Herbst 2002). However, the mechanism of endostatin action as a cancer treatment is 
incompletely known and the clinical responses have remained modest (Karamouzis 2009).   
2.4 GATA4 in ovarian function and GCTs 
The GATA factors are an evolutionarily conserved group of transcription factors that bind 
a specific A/T-GATA-A/G motif found in the regulatory regions of numerous genes 
(reviewed in (Viger 2008)). In vertebrates, the GATA family consists of six members 
(GATA1 to GATA6) that are crucial regulators of development and differentiation (Weiss 
1995). GATA1/2/3 regulate the development of the brain, spinal cord, and inner ear and 
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the differentiation of hematopoietic cell lineages. GATA4/5/6 are primarily expressed in 
tissues of mesodermal and endodermal origin such as the heart, gut, and gonads. 
   
GATA4 is a zinc finger transcription factor that plays a crucial role during fetal 
development; GATA4 null mutation is embryonic lethal due to defects in heart 
development (Molkentin 1997). GATA4 is required also for normal ovarian and testicular 
development (Bielinska 2007; Manuylov 2008). In the adult, GATA4 plays a role in 
follicular development, with granulosa cells being the major site of GATA4 expression 
(Laitinen 2000). During follicular development GATA4 expression is spatiotemporally 
regulated; the expression initiates in the proliferating granulosa cells of small preantral 
follicles, peaks in the antral follicles, and diminishes rapidly during ovulation, being 
virtually non-existent in luteal glands (Heikinheimo 1997; Laitinen 2000; Vaskivuo 2001; 
Anttonen 2003). In the ovary, FSH and TGF-β regulate the expression of GATA4 
(Heikinheimo 1997; Anttonen 2006). GATA4 has been shown to regulate granulosa cell 
proliferation and function (Anttonen 2006; Kyronlahti 2008), moderating many factors 
crucial for normal follicular development, including AMH (Tremblay 1999; Anttonen 
2006), aromatase (Tremblay 2001b), and α-inhibin (Anttonen 2006). A recent study on 
heterozygous and granulosa cell-specific conditional GATA4 knockout mice showed that 
GATA4 is crucial for normal follicular development and function (Kyronlahti 2011). 
 
In GCTs, GATA4 is expressed at levels comparable to preovulatory granulosa cells 
(Laitinen 2000; Anttonen 2005). Moreover, high expression of GATA4 has been 
associated with higher stage GCT and increased recurrence risk in GCT patients (Anttonen 
2005). Further, GATA4 putatively plays a role in GCT pathogenesis by inhibiting 
apoptosis; GATA4 activates the expression of the anti-apoptotic Bcl-2 and protects GCT 
cells from apoptosis (Kyronlahti 2008; Kyronlahti 2010). 
2.5 EGF receptors in ovarian function and GCTs 
Epidermal growth factor (EGF) is crucial during gonadal development and regulates 
granulosa cell function (Schomberg 1983). EGF is a member of a large group of growth 
factors that includes TGF-α, heparin-binding EGF-like growth factor, amphiregulin, 
epiregulin, betacellulin, epigen, and neuregulins (reviewed in (Conti 2006)). These ligands 
bind four related receptors, the EGF receptors. The complex network of signals is 
regulated by different combinations of ligands binding to homo- and heterodimeric 
receptors, leading to different cell-specific responses.   
 
EGF receptors are a group of transmembrane tyrosine kinase receptors that includes the 
EGF receptor EGFR/heregulin-1 (HER1), HER2/neu, HER3, and HER4. In the ovary, 
EGF receptor family members promote granulosa cell proliferation and survival (Conti 
2006; Zandi 2007), and normal EGFR signaling seems to be required for FSH response 
and steroidogenesis in granulosa cells (Jamnongjit 2005; Wayne 2007). No specific ligand 
has been found for HER2, but it can be transactivated via heterodimerization with other 
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HER2 receptors (Hynes 2005). After ligand binding, HER3 and HER4 dimerize and 
activate intracellular pathways to promote survival and proliferation; HER3 lacks the 
intracellular kinase domain, but contributes to intracellular signaling through 
heterodimerization with other HER receptors (Lemmon 2009). 
 
Overexpression and/or mutation of EGFR and HER2 have been shown to contribute to the 
progression of several human cancers, including brain, lung, breast, and ovarian cancers 
(Hynes 2005; Zandi 2007). The EGF receptors have been extensively studied in cancer 
therapy and are targeted with monoclonal antibodies or tyrosine kinase inhibitors in 
clinical trials (reviewed in (Tsujioka 2010)). GCTs also express EGFR (Leibl 2006) (N. 
Andersson, unpublished data), and positive expression has been found to be associated 
with worse prognosis (Nosov 2009). Further, EGFR inhibition was shown to induce 
apoptosis in GCT cells (N. Andersson, unpublished data).  HER2, HER3, and HER4 are 
also expressed in GCTs (Furger 1998; Leibl 2006) (see also Section 2.5.1), and HER3-4 
potentially mediate GCT cell survival in a GCT cell line (Furger 1998). The functional 
role of HER2 in GCT cells has not been studied. 
2.5.1 HER2 oncogene 
HER2 is overexpressed in 30% of breast cancers as a result of amplification of the gene 
encoding for HER2 (HER2) (Hicks 2008). This amplification is highly associated with 
worse overall survival in breast cancer (Slamon 1987). In epithelial ovarian cancer, HER2 
is overexpressed in 17-44% and amplified in 7-14% of tumors. Some studies have 
reported an association between HER2 expression and worse clinical outcome (Fajac 
1995; Felip 1995; Lassus 2004). HER2 is a therapeutic target in cancer therapy; currently, 
there are two drugs in clinical use targeting HER2 in the treatment of breast and metastatic 
gastric cancer: a monoclonal antibody trastutsumab (Herceptin®) and a small molecule 
HER2 tyrosine kinase inhibitor lapatanib (Tykerb®) (Stern 2012). 
 
Data on HER2 expression in GCTs are somewhat conflicting; two studies reported 
positive expression in GCTs (King 1996; Furger 1998), while others found GCTs to be 
negative for HER2 (Kusamura 2003; Leibl 2006; Mayr 2006; Menczer 2007). HER2 is 
also expressed in GCT cell lines KGN (N. Andersson, unpublished data), and COV343 
(Furger 1998). Copy number alterations of the HER2 gene were not described in a study 
including GCTs (Mayr 2006). 
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Aims of the study 
This study was undertaken to investigate regulators of tumor angiogenesis and granulosa 
cell function in GCT pathogenesis and to find new molecular prognostic factors and 
treatment options for GCT patients. 
 
Specific aims of the study were as follows: 
 
1) to investigate the functional role of AMH signaling and the role of VEGF and 
its receptors in GCT pathogenesis 
 
2) to evaluate the possibility of targeting AMH and VEGF pathways in the 
treatment of GCTs 
 
3) to identify new molecular prognostic markers for GCT 
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 Materials and Methods 
1. Patients (I-IV) 
The clinical data of 118 GCT patients diagnosed at Helsinki University Central Hospital 
from 1956 to 2010 were retrospectively collected. Fifty-four GCT patients were recruited 
with their informed consent to give blood samples and fresh tumor tissue upon surgery for 
expression analyses and cell culture experiments. All living GCT patients no longer in 
follow-up were invited for a clinical control, and 41 patients were clinically examined to 
gain an extended follow-up. The rest were followed from hospital files and the causes of 
death were collected from death certificates retrieved from the Finnish Causes of Death 
Registry. The Ethics Committee of Helsinki University Central Hospital (197/E9/06) and 
the National Supervisory Authority of Welfare and Health in Finland (decision number 
244/05.01.00.06/2009) approved the study protocol. 
2. Serum samples (II) 
Seventy-four serum samples of 54 GCT patients were collected from August 2007 to 
November 2011. The samples were prepared and stored at -80°C until analysis. Data on 
patient hemoglobin, leukocyte, hematocrite, and platelet counts were collected from 
samples drawn on the same days.  
3. Tissue samples (I-IV) 
A tumor tissue microarray (TTMA) of 80 primary and 13 recurrent GCTs from 90 patients 
was previously constructed (Anttonen 2005). Paraffin-embedded sections of the TTMA 
consisted of quadruple core samples of 93 GCTs on a single slide, and the tumor subtype, 
degree of nuclear atypia, and mitotic index were defined as described elsewhere (Anttonen 
2005) in accordance with WHO 2003 guidelines (F.A. Tavassoli 2003). The tumor size 
and histological characteristics in the TTMA are summarized in Table 2. Thirty-four fresh 
tumor tissue samples were collected from May 1994 to August 2009, and the samples 
were snap-frozen in liquid nitrogen and stored in -80°C until analyses. The ovaries from 
three premenopausal women operated on for cervical cancer were used as controls. From 
December 2007 to September 2010, we obtained eight primary and six recurrent GCTs for 
primary cell cultures (see Section 4).  
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Table 2. Summary of tumor size and histological parameters of 80 primary and 13 
recurrent GCTs in the TTMA. 
Factor Level Primary GCT (n=80) 
n (%) 
Recurrent GCT (n=13) 
n (%) 
Tumor size <10 cm in diameter 
≥10 cm in diameter 
48 (60.0) 
32 (40.0) 
10 (23.1) 
  3 (76.9) 
Subtype Differentiated 
Sarcomatoid 
56 (70.0) 
24 (30.0) 
  3 (23.1) 
10 (76.1) 
Nuclear atypia Low 
High 
62 (77.5) 
18 (22.5) 
  9 (69.2) 
  4 (30.8) 
Mitotic index Low 
High 
60 (75.0) 
20 (25.0) 
  8 (61.5) 
  5 (38.5) 
 
4. Cell lines (I,III) 
The KGN cell line (Dr. T. Yanase, Kyushu University, Fukuoka, Japan) was cultured as 
previously described in DMEM/F12 containing 10% FFCS (Nishi 2001). The GCT cell 
cultures were established as described elsewhere (Kyronlahti 2010); the fresh tumor 
sample was retrieved straight from the operation theater in cold PBS, mechanically 
minced, and incubated in 0,5% collagenase (Sigma-Aldrich® Corporation, St. Louis, MO, 
USA) for 2 hours, filtered through a 140 µm filter mesh, washed two times with cell 
culture supernatant, and the single cells were then plated for experiments in the 
DMEM/F12 containing 10% FFCS without passaging. KGN cells were used   All of the 
primary GCT cells as well as the KGN cells harbored the c.402CG (p.C134W) mutation 
in FOXL2. 
5. Expression analyses (I-IV) 
5.1 Immunohistochemistry and scoring of the results (I-IV) 
Paraffin-embedded sections (6 µm in thickness) of the TTMA and normal ovaries were 
subjected to IHC with the antibodies presented in Table 3. The sections were 
deparaffinized with xylene and rehydrated with ethanol incubations. Antigen retrieval was 
performed with 10 mM citric acid in a microwave oven for 10–20 min, and endogenous 
peroxidase was blocked with 3% hydrogen peroxide. Immunoperoxidase stain was 
performed as described elsewhere (Anttonen 2005) using an avidin-biotin 
immunoperoxidase system (Vectastain Elite ABC kit; Vector Laboratories, Burlingame, 
CA, USA) and DAB (Sigma, St. Louis, MO, USA) to visualize the bound antibody. The 
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sections were counterstained with hematoxylin. Images were acquired with an LS Leica 
DMRXA microscope using 20x and 100x magnifications, connected to an Olympus DP70 
camera and a DCP controller image acquisition program. The intensity of staining and the 
percentage of positive cells were scored for each antigen from four cores of each tumor by 
two independent researchers, and the tumors were divided into subgroups of high, 
medium, low, and negative, depending on the antigen. The threshold levels were defined 
individually for each antigen depending on the immunoreactivity and the localization of 
the antigen. Disagreements were resolved by a joint review. Tumor blood vessels were 
visualized with α-CD34 antibody, and the number of tumor blood vessels was counted per 
visual field. The microvessel density (MVD) was graded as high with ≥60 microvessels 
per visual field and as low with <60 vessels per visual field.  
Table 3. Antibodies utilized in IHC and Western blotting. * The antibody was kindly 
provided by Dr. Isabelle Navarro-Teulon (INSERM U896, Montpellier, France). 
 
Antigen Company Catalog no Dilution in IHC/WB 
AMHRII * (see heading)  1:50/1:5000 
Smad1 Abcam ab55476 1:50/1:1000 
Smad2 Invitrogen 51-1300 1:200/- 
Smad3 Invitrogen 51-1500 1:400/- 
Smad4 Santa Cruz Biotechnology Sc-7966 1:200/- 
Smad5 Abcam ab40771 1:50/1:2500 
P-Smad1/5 Cell Signaling Technology #9511S 1:100/1:2500 
P-Smad2/3 Cell Signaling Technology #3101S 1:500/- 
VEGF Santa Cruz Biotechnology sc-152 1:50/- 
VEGFR-1 Santa Cruz Biotechnology sc-316 1:100/- 
VEGFR-2 Santa Cruz Biotechnology sc-6251 1:200/1:500 
P-VEGFR-2 Abcam Y1214 1:70/1:500 
CD34 DAKO M7165 1:50/- 
HER2 Santa Cruz Biotechnology sc-33684 1:100/- 
HER3 Santa Cruz Biotechnology sc-415 1:50/- 
HER4 Santa Cruz Biotechnology sc-283 1:50/- 
Cleaved caspase-3 Cell Signaling Technology #9661L -/1:500 
Bcl2 DAKO MO887 -/1:500 
Cyclin D2 Santa Cruz Biotechnology sc-598 -/1:1000 
Beeta actin Santa Cruz Biotechnology sc-1616 -/1:5000 
5.2 PCR and quantitative PCR (I-III) 
The primers listed in Table 4 were either designed with IDT SciTools software or 
retrieved from the literature, and tested with in-silico PCR using the UCSC Genome 
Bioinformatics website for recognizing the correct mRNA transcript. The RNA was 
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isolated with a Nucleospin RNA/Protein kit (catalog no. 740 933.250, Macherey-Nagel, 
Düren, Germany) and purified with an RNA purification kit (Nucleospin RNA Clean up 
kit, catalog no. 740 948.50) according to instructions. Semi-quantitative PCR was 
performed as described previously (Salonen 2009). For qPCR, first-strand cDNA 
synthesis was performed from 0.8 µg of total RNA using SYBR GREEN RT-PCR 
reagents and random hexamers (Applied Biosystems, Foster City, CA, USA) according to 
instructions. Standard curve method was applied; purified mRNA from the KGN cell line 
or from pooled GCT samples was used as a standard. Analysis was performed with SYBR 
Green RT-PCR reagents and an ABI PRISM 7700 sequence detection system (Applied 
Biosystems) according to manufacturer’s instructions. All analyses were performed in 
triplicate. 
 
Table 4. Primers utilized in PCR and quantitative PCR (qPCR). 
 
Transcript Primers 5’-3’ Amplicon size  PCR type 
AMH F: CGCCTGGTGGTCCTACAC 
R: GAACCTCAGCGAGGGTGTT 
60 bp qPCR 
AMHRII F: TGTGTTTCTCCCAGGTAATCCG 
R: AATGTGGTCGTGCTGTAGGC 
F: TTTGGGGCTTTGGGCATTAC 
R: GATGCCGAGACAGTGAT 
164 bp 
 
238 bp 
qPCR 
 
PCR 
ALK2 F: TTAAAAGGCGCAACCAAGA 
R: CGTACAACGATCCCATTTCA  
423 bp PCR 
ALK3 F: TTTATGGCACCCAAGGAAAG 
R: TGGTATTCAAGGGCACATCA 
156 bp PCR 
ALK6 F: CTCAGGGAGCGACCTGGGCA 
R: GCGGCCCCAAATGCAGGGAT 
437 bp PCR 
Smad1 F: GCGGCATATTGGAAAAGGAG 
R: CCTGGGGCCATTTAAGAT 
429 bp PCR 
Smad5 F: GCGAAAAGGAAGCTGTTG 
R: ACCTTGTTTCCAGCCCA 
320 bp PCR 
Beta-actin F: CTGACGGCCAGGTCATCAC 
R: CAGACAGCACTGTGTTGGC 
174 bp qPCR 
VEGF F: TGCAGATTATGCGGATCAAACC 
R: TGCATTCACATTTGTTGTGCTGTAG 
82 bp qPCR 
VEGFR-2 F: GGAAGCTCCTGAAGATCTGT 
R: GAGGATATTTCGTGCCGC 
139 bp qPCR 
GAPDH F: TCATTTCCTGGTATGACAACG 
R: TTACTCCTTGGAGGCCATGT 
80 bp qPCR 
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5.3 Western blotting (I, III) 
The extracted protein was separated by 7.5% SDS-PAGE and transferred onto an 
Immobilon-P membrane (Millipore, Bedford, MA, USA). Beta-actin was used as a 
loading control. Nonspecific binding was blocked with 5% nonfat milk in 0.1% Tris-
buffered Tween-saline buffer. Primary and secondary antibodies were incubated for 1 h at 
room temperature. The proteins were visualized with the Enhanced Chemiluminescence 
Plus Kit (Amersham Biosciences Inc., Piscataway, NJ, USA).  
5.4 ELISA assays (I-III) 
The serum and cell culture supernatant samples were analyzed in duplicate according to 
manufacturers’ instructions with enzyme-linked immunosorbent assays (ELISAs): VEGF 
#DVE00 (R&D Systems, Minneapolis, MN, USA), endostatin #DNST0 (R&D Systems), 
and AMH #DSL-10-14400 (Beckman Coulter Inc., Webster, TX, USA).  
5.5 Silver in situ hybridization (IV) 
Paraffin-embedded sections of the TTMA were utilized for Silver in situ hybridization 
(SISH) for the HER2 DNA and chromosome 17 probes with Inform® (Ventana Medical 
Systems, Tucson, AZ, USA). The automated SISH was performed according to the 
manufacturer’s instructions (Dietel 2007), with slight modifications; the hybridization 
time for the HER2 probe was 10 and for the chromosome 17 probe 8 h. 
6. Cell cultures and treatments (I, III) 
The primary GCT and KGN cells were subjected to AMH, BVZ, or control treatments for 
1-5 days. BVZ 25 mg/ml was purchased from Genentech/Roche (San Francisco, CA, 
USA). Recombinant human AMH (rhAMH) was purified and tested for bioactivity as 
described earlier (Donahoe 2003).  The cells were treated at different concentrations and 
followed by apoptosis, proliferation, cell viability assays (see Section 6.1), or protein 
extraction (Nucleospin RNA/Protein kit, catalog no. 740 933.250, Macherey-Nagel, 
Düren, Germany). For cell culture supernatant collection, 200 000 primary GCT cells and 
KGN cells were plated to 6-well chambers containing 2 ml of DMEM/F12 with 10% 
FFCS, the culture supernatant was collected after 2-4 days (depending on the confluence), 
and the supernatants were stored at -20OC until analysis.  
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6.1 Apoptosis, proliferation, and cell viability assays  
For apoptosis analyses, 20000 KGN and primary GCT cells were seeded on 96-well plates 
(Caspase assay, see below) or 8-well glass chambers (DAPI staining, see below). Caspase-
Glo® 3/7 assay (Promega Corporation, Madison, WI, USA) was utilized according to the 
manufacturer’s instructions. DAPI staining was performed as described (Kyronlahti 2010), 
and the percentage of apoptotic cells in 1200-3000 total cells was determined with 
ImageJTM 1.42q software (National Institutes of Health, Bethesda, MD, USA). 
 
For cell proliferation analyses, a bromodeoxyuridine (BrdU) staining kit (Invitrogen, 
Carlsbad, CA, USA) was utilized according to the manufacturer’s instructions, and the 
proportion of BrdU-positive cells was determined from 2000–3000 cells on 8-well glass 
chamber slides. For cell viability assays, a tetrazolium dye (MTT)-based cell growth 
determination kit (#CGD1, Sigma-Aldrich Corporation) was utilized for cell viability 
assay; 10000 KGN cells were plated on 96-well plates, and the kit was utilized according 
to the manufacturer’s instructions. 
7. Database and statistical analyses (I-IV) 
File Maker Pro 10.0v3 software was used to construct a database of the patients, including 
full clinical data, serum samples, tissue samples, and follow-up and survival data. The 
patients were encoded with study ID numbers. The data consisted of up to 500 data fields 
per patient, and the sample data were linked to patient details based on study ID number. 
The data were exported as a Microsoft Exel file and transported to statistics software for 
analyses. The clinical data of the patients regarding recurrences and survival were updated 
twice during this study: in September 2009 and in May 2011. The results on IHC, 
quantitative PCR analyses, and serum analyses were stored in the database. 
 
The statistical analyses were carried out with JMP® 9.0.0 software (SAS Institute Inc., 
Cary, NC, USA). The immunohistochemical data and the categorical variables were 
analyzed with contingency tabling (2x2) and chi-square or Fisher’s exact tests when 
appropriate. The continuous variables were analyzed with linear regression using 
Pearson’s correlation coefficient. The serum data were tested for normal distribution with 
Shapiro-Wilks test and analyzed with one-way ANOVA and Student’s t-test upon normal 
distribution, or with Wilcoxon/Kruskall-Wallis and Wilcoxon matched-pairs sign-rank 
tests when differing from normal distribution (serum VEGF data). Upon comparison with 
normally distributed variables, a logarithmic transformation was performed on the serum 
VEGF data. The cell culture data and mRNA expression data were analyzed with one-way 
ANOVA, followed by Dunett’s or each pair Student’s t-test. Kaplan-Meier was performed 
according to the methodology using a log-rank test. Multivariate analyses were conducted 
using a nominal logistic regression model and a Cox proportional hazards model. P<0.05 
was considered statistically significant.  
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Results and Discussion 
1. Expression profile of GCTs (I-IV) 
Tumor growth is dependent on the expression of growth and transcription factors that 
regulate cell proliferation and survival as well as angiogenesis. We set out to analyze 
protein and mRNA expressions of several factors closely related to granulosa cell function 
and angiogenesis in GCTs: AMH and its receptors, VEGF and its receptors, and EGF 
receptors. 
1.1 Protein expression profile in TTMA  
The TTMA of 80 primary and 13 recurrent GCTs was analyzed with 
immunohistochemistry for the different antigens. Based on the intensity of staining and 
the percentage of positive cells, the tumors were further divided into “high” and “low” 
expressing groups, the latter also including the negative tumors. A summary of the TTMA 
scoring results of all of the factors studied here, as well as the results on tumor MVD and 
HER2 gene amplification is presented in Table 5.  
 
AMHRII and its signaling cascade components were expressed in GCTs, also in 
phosphorylated, i.e. activated, state. VEGF and its receptors were expressed, and VEGFR-
2 also in the phosphorylated state in the majority of GCTs. HER2-4 expression was also 
detected; however, amplification of the HER2 gene was rare. The correlations and 
biological roles of the factors are further discussed below (Sections 2-4). 
    
The TTMA proved to be a good tool for screening and evaluating expression levels of the 
different factors. Although subjective, two independent researchers performed the 
analysis, and a consensus of the classification of the tumors to two or three expression 
levels was achieved for all available samples. For some of the samples, the core samples 
represented only connective tissue or were lacking from the section, and therefore, the 
numbers do not total 93 in all analyses. Compared with evaluating 93 serial slides for 
expression levels, the TTMA putatively provides a more reliable and reproducible tool to 
screen for prognostic factors and biological associations between different tumors 
(Kononen 1998). Based on the complete clinical details and follow-up data of the patients, 
we were able to screen for prognostic factors for GCT in the TTMA (see Section 4).  
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Table 5. Summary of expression levels of the studied factors and the degree of microvessel 
density (MVD) and HER2 gene amplification (SISH) in the TTMA of 80 primary 
and 13 recurrent GCTs. The tumors were divided to ”High” and “Low” 
expression groups; the “Low” group also includes negative tumors. “Ampl” in 
HER2 SISH indicates low-level (3-6) amplification of HER2 gene. GATA4 
expression was previously described in Anttonen 2005. 
Factor Level Primary GCT n(%) Recurrent GCT n(%) 
AMHRII High 
Low 
45 (57.0) 
34 (43.0) 
6 (54.5) 
5 (45.5) 
Smad1 High 
Low 
37 (48.6) 
46 (51.3) 
4 (33.3) 
8 (66.7) 
Smad2 High 
Low 
53 (67.1) 
26 (32.9) 
12 (92.3) 
1 (7.7) 
Smad3 High 
Low 
32 (43.2) 
42 (56.8) 
4 (30.7) 
9 (69.2) 
Smad4 High 
Low 
58 (76.3) 
18 (23.6) 
12 (92.3) 
1 (7.7) 
Smad5 High 
Low 
57 (76.0) 
18 (24.0) 
5 (41.7) 
5 (58.3) 
P-Smad1/5 High 
Low 
49 (62.8) 
29 (37.1) 
7 (58.3) 
5 (41.7) 
P-Smad2/3 High 
Low 
52 (66.7) 
26 (33.3) 
10 (83.3) 
2 (16.7) 
VEGF High 
Low 
56 (72.7) 
21 (27.3) 
9 (81.8) 
2 (18.2) 
VEGFR-1 High 
Low 
11 (14.3) 
66 (85.7) 
5 (45.5) 
6 (54.5) 
VEGFR-2 High 
Low 
71 (92.2) 
6 (7.8) 
11 (100.0) 
0 
P-VEGFR-2 High 
Low 
17 (22.1) 
60 (77.9) 
4 (33.3) 
8 (66.7) 
MVD High 
Low 
19 (24.1) 
60 (75.9) 
6 (50.0) 
6 (50.0) 
HER2 High 
Low 
17 (22.7) 
58 (77.3) 
4 (33.3) 
8 (66.7) 
HER2 SISH Ampl 
No 
8 (10.1) 
71 (89.8) 
0 
12 (100.0) 
HER3 High 
Low 
18 (23.1) 
60 (76.9) 
4 (33.3) 
8 (66.7) 
HER4 High 
Low 
54 (72.9) 
20 (27.0) 
10 (83.3) 
2 (16.7) 
GATA4 High 
Low 
34 (42.5) 
46 (57.5) 
5 (38.5) 
8 (61.5) 
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1.2 mRNA expression profiles 
The mRNA of 34 freshly frozen GCT samples was analyzed with quantitative PCR for the 
expression of the factors listed in Table 6. Because of variation in the conditions between 
analyses and standard curves, all correlations between factors should be made from a 
single PCR run, and using the same reference gene. This was achieved in the study; 
however, the results are only comparable with the genes analyzed in the same setting. 
Therefore, the results can be summarized through rough estimates when compared with 
the reference gene (Table 6). In addition, there were only 11 samples for which both 
mRNA and IHC were available in the TTMA, and for most of the factors the numbers 
were too small to detect correlations between mRNA and protein expression levels. The 
roles of the different factors are further discussed below (Sections 2-4).  
Table 6. Summary of quantitative PCR analysis of mRNA expression levels in 28 primary 
and 6 recurrent GCT samples. + indicates low expression, ++ indicates medium 
expression, and +++  high expression compared with the reference gene (GAPDH 
or Beta-actin).  
 
Factor mRNA expression level 
AMH + 
AMHRII + 
VEGF ++ 
VEGFR-2 +++ 
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2. AMH is a growth inhibitor of GCTs (I) 
AMH is a crucial regulator of granulosa cell function. AMH is expressed in GCTs 
(Anttonen 2005), and mouse models suggest a role for AMH in GCT pathogenesis 
(Pangas 2008; Edson 2010). We elaborated the functional role of AMH in GCTs by 
characterizing the expression of the AMH receptors and the downstream signaling 
molecules (Smads) (Section 2.1) and by describing the effect of exogenous AMH on GCT 
cell proliferation and apoptosis in vitro (Section 2.2).  
2.1 Expression of AMH and its receptors in GCTs 
The TTMA was utilized for IHC, and 34 tumor tissue samples were used for Western 
blotting and PCR for the expressions of the AMH and its receptors; the results are 
summarized in Figure 6. We found that AMHRII expression was characteristic of GCTs; 
AMHRII expression was detected in 96% of GCTs, while the expression was high in 57% 
of the tumors. Only three tumors (4%) were negative for AMHRII. Western blotting of 
AMHRII was positive in all 34 tumors analyzed. Further, all of these tumors expressed 
AMHRII at the mRNA level. Moreover, the type I AMH receptors ALK2, ALK3, and 
ALK6 were expressed in GCTs. The AMH receptors were equally expressed in primary 
and recurrent GCTs. Furthermore, the levels of AMHRII expression were similar to those 
observed in a previous study of GCTs (Song 2009). However, AMHRII expression was 
higher in GCTs than reported in epithelial ovarian cancers (Bakkum-Gamez 2008; Song 
2009). 
 
AMHRII expression correlated positively with AMH expression at the protein as well as 
at the mRNA level (I: Figure 1 b, Table 2). At the protein level, AMHRII expression also 
correlated with P-Smad1/5 expression, indicating active AMH-AMHRII-P-Smad1/5 
signaling in GCTs. P-Smad1/5 expression strongly and positively correlated with Smad5 
expression, indicating that Smad5 could be the prominent form of phosphorylated Smads 
in GCTs. AMH protein expression also correlated positively with expression of Smad1, 
Smad5, and P-Smad1/5. Together, these data indicate that AMH signaling cascade 
components are expressed by and colocalize in GCTs.  
 
Our group previously described AMH protein expression to be decreased in large GCTs 
(Anttonen 2005). We could now confirm this result at the mRNA level (Figure 9 B), 
supporting the role of AMH as a growth inhibitor in GCTs. Moreover, mouse models 
suggest that disruption in the balance between AMH/BMP-type signaling (Smad1/5) and 
pro-tumorigenic TFG-β-activin signaling (Smad 2/3) contributes to GCT pathogenesis 
(Pangas 2008; Middlebrook 2009). Interestingly, we observed that P-Smad2/3 and P-
Smad1/5 were equally expressed in GCTs less than 10 cm in diameter (n=55), and a 
positive correlation existed between the P-Smad1/5 and P-Smad2/3 (p=0.0058). By 
contrast, in larger tumors (≥10 cm in diameter, n=35), the balance was disrupted and no 
correlation was found (A. Färkkilä, unpublished data). 
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To further analyze the role of AMH in GCTs, we measured AMH levels from the cell 
culture supernatant of the KGN cell line and primary GCT cells. We found that cultured 
GCT cells produced detectable levels of AMH in the supernatant; average levels were 0.68 
ng/ml (range 0.41-1.06 ng/ml) for KGN and 0.77 ng/ml (range 0.43-1.71 ng/ml) for 
primary GCT cells after 1- to 5-day incubations.  
 
Based on the expression of both AMH and its receptors in GCTs, AMH putatively has an 
auto/paracrine regulatory function in GCTs. However, Chang et al. reported that at the 
serum level AMH positively correlates with tumor size (Chang 2009). This discrepancy 
between tissue and serum AMH levels may be explained by a growth inhibitory role of 
AMH in the tumor microenvironment; in a subset of tumors, the reduced AMH levels may 
lead to increased TGF-β-type signaling. These cancer cells then escape the AMH-
controlled growth inhibition, leading to increased growth potential of the tumor. A similar 
phenomenon is seen in large antral follicles of the ovary; the reduced AMH levels in 
highly proliferating granulosa cells may be one of the factors promoting the rapid growth 
of the follicle (Weenen 2004). In larger GCTs, how and why AMH levels decrease are 
unknown.  
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Figure 6. Summary of the expression analyses of AMH, AMH receptors, and Smad1, Smad5, 
and phosphorylated Smad1/5 in GCTs (I). AMH type I receptors (Alk2, -3, and -6) 
and AMHRII, as well as the downstream effectors Smad1 and -5 were readily 
expressed in GCTs as analyzed with PCR in 26 primary and 4 recurrent (no. 21, 
24-26) GCTs (A). Real-time PCR of 28 GCTs revealed decreased AMH levels in 
large GCTs (p=0.0391) (B). Representative images of the immunostainings in 
normal granulosa cells (row 1) and GCTs (rows 2-4). High magnification (100x) 
images of the high-staining group are presented in row 3. An asterisk marks the 
normal granulosa cells in the lining of an antral follicle (row 1). Scale bars 200 
µm in C (A-L). 
 
 
A 
 
B 
 
C 
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2.2 AMH treatment of GCT cells in vitro 
Based on the expression analyses, AMH is putatively a growth inhibitor in the tumor 
microenvironment, and we next wanted to explore the functional effects of recombinant 
human AMH (rhAMH) on GCT cells in vitro. In KGN cells, we saw that rhAMH 
significantly decreased cell number relative to the control (AMH 0 µg/ml) during 3- and 
10-day incubations (Figure 7 A). AMH had, however, no significant effect on cell 
proliferation (Figure 7 B). Similar results were obtained from two cases of primary GCT 
cells (Figure 7 C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Summary of the effects of rhAMH on cell number and proliferation of GCT cells 
(I). The KGN and two primary GCT cell cultures were treated with increasing 
rhAMH concentrations for 1-10 days and analyzed with MTT assays (A, B) or 
BrdU incorporation assay (C). The MTT data are presented as the relative 
number of viable cells compared with the control (AMH 0 µg/ml) (A, B); 10% 
FFCS was used as a control and 1% FFSC as a control for growth factor 
deprivation. The proliferation of KGN cells with AMH treatment is shown as a 
proportion of BrdU-positive cells (C). Data are presented as mean ± SD from two 
(B) or three independent experiments (A, C).  
A 
S 
C 
B Relative optical density (550 nm) % of BrdU-positive cells A 
Relative optical density (550 nm) 
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In view of rhAMH treatment decreasing the cell number without an effect on cell 
proliferation, we studied whether AMH signaling is active and potentially induces 
apoptosis in GCT cells. We found that rhAMH was able to induce Smad1/5 
phosphorylation in KGN cells, indicating that the signaling cascade is functional in GCTs 
(Figure 8 A). rhAMH treatment also increased the expression of caspase 3, the enzyme for 
the committed step in apoptosis (Figure 8 A). Similar results were obtained in a primary 
GCT cell culture after 2- and 5- day incubations (Figure 8 B). Morphological apoptosis 
was seen in DAPI staining of the tumor cells after rhAMH treatment (Figure 8 C). In KGN 
cells, rhAMH treatment induced a significant increase in caspase 3/7 activity (I: Figure 4 
B) and in the percentage of apoptotic cells (I: Figure 4 C), altogether resulting in an 
approximately 2-fold increase in apoptotic cells. 
 
Figure 8. AMH induces apoptosis in KGN (A) and primary GCT cells (B, C) (I). Western 
blotting revealed an increase in Phospho-Smad 1/5 and cleaved caspase-3 with 
AMH treatment. The levels of Smad1, Smad5, Bcl2, and CyclinD2 remained 
unchanged, and beta-actin served as a loading control. Similar activation of 
cleaved caspase-3 was seen in a primary cell culture of a recurrent GCT (B), and 
DAPI staining confirmed increased morphological apoptosis (C) with AMH 
treatment. 
 
B 
C AMH (0µg/ml) AMH (5µg/ml) 
A 
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These results on the apoptosis-inducing effect of AMH on AMHRII-positive GCTs are in 
line with a previous study from epithelial ovarian cancer cells (Ha 2000). In epithelial 
ovarian cancer, AMH was able to inhibit growth of AMHRII-positive cancers in vitro 
(Chin 1991; Masiakos 1999; Ha 2000; Wei 2010) and in vivo (Stephen 2001; Stephen 
2002; Pieretti-Vanmarcke 2006a; Pieretti-Vanmarcke 2006b). In these models, AMH 
effect was characterized by apoptosis and mediated through AMHRII (Masiakos 1999; Ha 
2000). However, there are some problems when considering AMH treatment for GCTs. 
AMH protein must be fully cleaved to gain biological activity and to bind to AMHRII 
(Pepinsky 1988; MacLaughlin 1992; di Clemente 2010; Papakostas 2010). The production 
of purified, fully cleaved AMH was achieved only recently (di Clemente 2010), and the 
therapeutic effects of AMH in GCT remain to be evaluated in a more clinical setting. In 
GCT patients, AMH levels are also elevated in the serum (Long 2000; Chang 2009), and 
the mechanism of exogenous AMH as a therapeutic agent is questionable. A promising 
future alternative is the targeting of AMHRII with activating antibodies (Yuan 2006) or 
small molecule agonists (Renlund 2008; Wei 2010), especially in cancers expressing high 
levels of AMHRII such as GCT ((Song 2009) and I). Currently there are no cancer drugs 
targeting AMH or AMHRII in clinical trials. In view of these findings and the high 
expression of AMHRII in GCTs, and the low expression in normal tissues, AMHRII is a 
potential target for cancer therapy in advanced or poor-prognosis GCT patients.  
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3. VEGF is pro-tumorigenic in GCTs (II, III) 
Angiogenesis is a critical step in tumor progression (reviewed in (Carmeliet 2005)). VEGF 
is a key factor in tumor angiogenesis, while VEGFR-2 is the primary receptor transmitting 
the VEGF signals (Shalaby 1995). GCTs are highly vascularized tumors, but little is 
known about the functional role of VEGF in GCTs. We set out to analyze the expression 
of VEGF and its receptors in GCTs (Section 3.1) and further analyzed the functional role 
of soluble VEGF in GCTs (Sections 3.2 and 3.3) using tissue samples and cell cultures.   
3.1 Expression of VEGF and its receptors in GCTs  
The TTMA was stained for VEGF and its receptors and tumor MVD was analyzed 
concurrently with CD34 staining (Figure 9). We found that VEGF protein was expressed 
in the vast majority of GCTs; 96% of the tumors were positive, and 75% exhibited high 
expression (Table 5). The expression of VEGF was higher in GCTs than in granulosa-
lutein cells. In GCTs, the expression of VEGFR-1 was weak, whereas VEGFR-2 
expression was strong; 99% of the tumors were positive, and high expression was seen in 
93% (Table 2). In addition to the tumor blood vessels (arrow in inset of Figure 9 C), 
VEGFR-2 was also highly expressed in the cytoplasm of the tumor cells (Figure 9), as 
compared with granulosa-lutein cells. Medium to high levels of the transcripts of VEGF 
and VEGFR-2 were also present in GCTs (Table 6), whereas low levels of VEGFR-1 were 
detected only in conventional PCR (data not shown). Moreover, we found that 
phosphorylated VEGFR-2 (pVEGFR-2) was expressed in 82% of the tumors, and quite 
surprisingly, the majority of GCTs (95%) expressed P-VEGFR-2 in the nuclei of tumor 
cells (inset in Figure 9 E). The expressions of VEGF and VEGFR-2 correlated positively 
at protein and mRNA levels and the expression of pVEGFR-2 correlated positively with 
that of VEGF, VEGFR-1, and native VEGFR-2. VEGF and the receptors were equally 
expressed in primary and recurrent tumor samples. 
 
Normally in blood vessel endothelial cells, the expression of VEGFR-2 is autoregulated 
by VEGF; prolonged exposure of high levels of VEGF lead to decreased expression of the 
VEGFRs (Wang 2000). In cancer cells, VEGFR-2 is frequently expressed and active 
(Masood 2001; Fox 2004; Koukourakis 2011) and autocrine and paracrine VEGF-
VEGFR-2 signaling has been reported to lead to a survival-promoting autoloop in ovarian 
(Sher 2009), breast (Weigand 2005), and various other cancers (Masood 2001). As in 
normal granulosa cells (Greenaway 2004), we found that the expression of VEGF and its 
receptors colocalize in GCTs. Moreover, GCTs expressed both the ligand and the receptor 
in an activated state, suggesting auto- or paracrine VEGF-VEGFR-2 signaling in GCTs. 
 
After VEGF binding, VEGFR-2 can be transferred to the nucleus (Feng 1999; Fox 2004; 
Blazquez 2006). This is in line with the findings in this study; native VEGFR-2 was found 
to localize on the cell membranes and in the cytoplasm (II), and pVEGFR-2 was 
predominantly expressed in the nuclei of GCT cells (III). The different VEGF isoforms 
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also differ in their nuclear localization (Zhang 2000), and the role of nuclear pVEGFR 
putatively mediates different responses depending on different VEGF isoforms, 
phosphorylated tyrosine residues, and cell types (Zhang 2000; Fox 2004). In GCTs, 
nuclear pVEGFR expression correlated with VEGF expression and high tumor MVD, 
suggesting autocrine VEGF signaling to promote tumor angiogenesis. In addition, the 
prominent expression of VEGFR-2 also in an activated form provides a molecular basis to 
target VEGFR-2 also in the treatment of GCTs and support the premise that anti-VEGF 
treatments have direct effects on GCT cells.  
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Figure 9. Expressions of VEGF (A), and its receptors VEGFR-1 (B) and VEGFR-2 (C), and 
phosphorylated VEGFR-2 (E) in GCTs (II, III). CD34 was used to visualize the 
tumor blood vessels (D). Negative control (F). Scale bars 100 µm in D and 50 µm 
in the inset in E.  
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3.2 VEGF and endostatin in serum of GCT patients and tumor cell cultures 
(III) 
Increased levels of circulating levels of VEGF have been reported in ovarian cancer 
patients and correlate with worse prognosis (Li 2004). We explored the expressions of 
serum VEGF and endostatin in 54 GCT patients before and after tumor treatment (Figure 
10). We found that VEGF levels were elevated in patients with GCT (mean 292.6 pg/ml, 
range 19.0-1108.4, standard error; SE 43.4) and lower in patients free of disease (mean 
150.8 pg/ml, range 7.9-530.4, SE 31.0) (p=0.04, Figure 10 A). Further, in paired analyses 
of 20 GCT patients, serum VEGF levels decreased significantly after tumor removal 
(p=0.002). Serum VEGF levels were not significantly higher in patients with larger tumors 
(≥10 cm in diameter) than in patients with smaller tumors (<10 cm in diameter). The 
biological variation of serum VEGF is wide even in healthy subjects (Yamamoto 1996), 
and in this study the serum VEGF levels were not very high in GCT patients; the levels 
were comparable with those of early stage epithelial ovarian cancer patients (Li 2004). 
This is in line with the majority of GCTs in our study presenting at an early stage. 
 
Serum endostatin levels have been reported to be elevated in breast and renal cancer 
patients (Feldman 2000; Zhao 2004). In GCT patients, we found lower serum endostatin 
levels (mean 135.3 ng/ml, range 67-213, SE 9.1) than in disease free patients (mean 161.3 
ng/ml, range 87-264, SE 5.9) (p=0.01, Figure 10 B). We also observed decreased levels of 
serum endostatin in patients with larger tumors (p=0.02). In paired analyses, serum 
endostatin levels increased after tumor removal (p=0.01). Serum VEGF and endostatin 
levels did not correlate with each other, unlike findings in breast (Zhao 2004) and renal 
cell (Feldman 2000) cancers. Neither serum VEGF nor endostatin levels correlated with 
patient’s age, tumor treatment, or blood hemoglobin, hematocrite, leukocyte, or platelet 
counts.  
 
We next analyzed the production of VEGF and endostatin by cultured GCT cells to further 
evaluate the source of circulating VEGF and endostatin in GCT patients. We found that 
the KGN cell line and primary GCT cells produced significant amounts of VEGF in the 
supernatant. This finding suggests that the circulating VEGF is produced by the tumor, 
which is supported by the decrease in VEGF levels after tumor removal. By contrast, 
endostatin production by the GCT cells was extremely low. The exact source of 
circulating endostatin is not known, but it may be proteolytically released from the ECM, 
particularly in the liver (Schuppan 1998). These data suggest that the high VEGF and low 
endostatin levels in the serum and in the tumor microenvironment may favor angiogenesis 
and promote tumor growth in GCTs. Therefore, serum VEGF or endostatin are of limited 
value as tumor markers for GCT. However, elevated serum VEGF levels may reflect 
excessive production by the tumor, thus presenting VEGF as a potential target for therapy.  
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Figure 10. Serum VEGF is elevated and endostatin is decreased in GCT patients (III). Serum 
VEGF (A) and endostatin (B) levels were measured from the serum of 54 GCT 
patients, and the samples were analyzed based on disease presence. WD = with 
disease, DF =disease-free. An asterisk indicates a significant difference at 
p<0.05. 
3.3 Anti-VEGF treatment of GCTs in vitro (III) 
Based on the findings that GCTs produce VEGF and express VEGFR-2 also in activated 
form, we hypothesized that VEGF acts as an autocrine or paracrine survival factor in 
GCTs. We next wanted to further elaborate the functional role of endogenous VEGF in 
GCTs. The GCT cell line (KGN) and primary GCT cells were treated with a humanized 
monoclonal anti-VEGF antibody bevacizumab (BVZ) to block endogenous VEGF. In 
KGN cells, we found that BVZ significantly increased caspase 3/7 activity (Figure 11 A) 
and decreased the number of viable cells (Figure 11 B). The higher dose of BVZ (10 
µg/ml) induced roughly 4- to 7-fold increases in apoptotic cells in DAPI analyses. Similar 
results were seen in six primary GCT cell cultures; a mean 2.5-fold increase in apoptosis 
and activation of caspase 3/7 occurred (III, Figure 5). In addition, inhibition of 
endogenous VEGF with BVZ decreased the phosphorylation of pVEGFR-2 (Figure 11 C) 
in KGN cells. 
 
These results are in line with findings in ovarian and breast cancers, where functionally 
active VEGFR-2 is expressed on cancer cells, suggesting a survival-promoting VEGF-
B A 
* * 
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VEGFR-2 autoloop in cancer cells (Weigand 2005; Sher 2009; Spannuth 2009). The 
treatment of ovarian cancer cells with anti-VEGFR-2 treatment suppressed growth in vitro 
and in vivo (Spannuth 2009). In GCTs, by blocking the endogenous VEGF signalling with 
BVZ, we could induce apoptosis and a decrease in the number of viable cells. The BVZ 
doses used in this study were somewhat lower than in other in vitro studies (Sims 2008; 
Hasan 2011). The relative doses in clinical use are higher as well, corresponding to 
circulating levels of up to 250 µg/ml (Herbst 2005). BVZ inducing apoptosis in relatively 
small doses indicates that VEGF is essential for GCT cell survival. These results suggest a 
survival-promoting VEGF-VEGFR-2 autoloop in GCT cells. Furthermore, our findings 
implicate that BVZ inhibits growth of GCT cells, and demonstrate in vitro biological 
activity of BVZ in GCTs.  
 
Targeting VEGF may have severe adverse effects (Tanyi 2011), and tumors may become 
resistant to anti-VEGF therapy (Abdullah 2011). Targeting of VEGFR-2 shows promise as 
anti-cancer treatment in advanced non-small cell lung cancer and colorectal cancer 
patients (Drevs 2007; Schiller 2009). One of the most advanced drugs targeting VEGFR-2 
is Ramucirumab®, a fully human VEGFR-2 receptor antagonist that blocks the binding of 
the ligand to VEGFR-2. Ramucirumab® is currently being investigated in clinical trials 
for the treatment of several cancers including brain, breast, gastric, lung, colorectal, 
urinary tract, prostate, and ovarian cancers (www.clinicaltrial.gov). In cancer research, the 
VEGF-VEGFR-2 pathway may be targeted with other approaches, including small 
molecule tyrosine kinase inhibitors (reviewed in Saharinen 2011). Based on our results, 
targeting VEGF/VEGFR-2 may present a therapeutic option also in advanced or recurred 
GCTs. The effects of VEGF-targeted treatments on GCT patients remain to be further 
addressed in international, multi-center clinical trials.  
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Figure 11. Treatment of KGN cells with bevacizumab induced an increase in apoptosis (A), a 
decrease in the number of viable cells (B), and a decrease in VEGFR-2 
phosphorylation (C) (III). 
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4. Prognostic factors in GCTs (I-IV)  
4.1 Analysis of recurrence and survival of the study cohort  
To analyze the GCT recurrences and survival of the study cohort in the TTMA, the 
clinical data of the patients were collected in the GCT database, and follow-up and 
survival data were retrieved from hospital files and the Finnish Death Registry. The 
clinical characteristics of 80 primary GCT patients are summarized in Table 7. 
Table 7. Summary of clinical characteristics and their relation to recurrences in a cohort 
of 80 primary GCT patients. Mp= menopause, C=adjuvant chemotherapy, R= 
adjuvant radiotherapy  
 
Characteristic All patients 
n=80 
n (% of total) 
No recurrence 
n=62 
n (% of 
characteristic) 
Recurrence 
n=18 
n (% of 
characteristic) 
Age at diagnosis, years  
Mean (range) 
 
51.6 (19-87) 
 
52.3 (19-87) 
 
49.2 (28-76) 
Year of diagnosis 
Mean (range) 
 
1989 (1971-2003) 
 
1990 (1971-2003) 
 
1987 (1973-2001) 
Mp status:   
Premenopausal 
Postmenopausal 
 
37 (46.2) 
43 (53.8) 
 
25 (67.6) 
37 (86.0) 
 
12 (32.4) 
6 (14.0) 
Stage          I 
                            Ia 
                            Ib 
                            Ic 
                   II 
                   III 
71 (88,8) 
50 (70.4) 
1 (1.4) 
20 (28.2) 
6 (7.5) 
3 (3.8) 
56 (78.9) 
40 (80.0) 
1 (100) 
15 (75.0) 
4 (66.7) 
2 (66.7) 
15 (21.1) 
10 (20.0) 
0 (0) 
5 (25.0) 
2 (33.3) 
1 (33.3) 
Treatment:   
Surgery only 
Surgery + C 
Surgery + R               
Surgery + C + R 
 
65 (81.3) 
12 (15.0) 
1 (1.3) 
2 (2.5) 
 
50 (76.9) 
10 (83.3) 
0 (0) 
2 (100) 
 
15 (23.1) 
2 (16.7) 
1 (100) 
0 (0) 
Follow-up time, years 
Mean (range) 
 
16.8 (0.06 – 36.7) 
 
17.1 (0.06 – 36.7) 
 
15.7 (4.6 – 33.9) 
Survival: 
Alive 
Dead of GCT 
Dead of other 
  
51 (63.8) 
11 (13.8) 
18 (22.5) 
 
44 (86.3) 
1 (9.1) 
17 (94.4) 
 
7 (13.7) 
10 (90.9) 
1 (5.6) 
 
RESULTS AND DISCUSSION 
 
 
 
 
 48 
Eighteen (22.5%) of the patients had a recurrence during the study period. Up to 20% of 
even stage Ia patients developed a recurrence (Table 7). The median time to recur was 7.0 
years (range 2.6-18.4 years, mean 7.7, SD 4.5).  Six (33.3%) of the recurrences occurred 
within 5 years, 14 (77.8%) within 10 years, and 17 (94.4%) within 15 years of the 
diagnosis. One patient had a recurrence 18.4 years after the primary diagnosis. None of the 
characteristics in Table 7 was associated with an increased risk of tumor recurrence. 
Tumor stage was not a prognostic factor for recurrence (Figure 13 A, B). There was no 
difference in the recurrence probability between stage I and stage II-III patients (Figure 13 
A). However, an increased risk of recurrence was seen within 5 years of diagnosis in stage 
Ic patients relative to stage Ia-b patients (HR 10.64, 95% CI 1.57-208.12, p=0.0142), but 
the difference was not significant after 10 and 15 years or during the follow-up period 
(Figure 13 B). The mean time to recur for stage Ia-b patients was 9.3 years (95% CI 5.90-
12.62 years), and for stage Ic patients 5.4 years (95% CI 0.42-10.46 years). This may be 
explained by in stage Ic disease, the tumor cells being disseminated into the abdominal 
cavity, predisposing to the typical local recurrence of GCT. 
 
Although GCTs are characterized by a tendency towards late recurrence, almost 80% of 
the recurrences develop within 10 years of the primary diagnosis, and recurrences after 15 
years are rather uncommon. Further, only one-third of the recurrences were seen within 
the first 5 years. In this study, a follow-up of over 10 years was achieved in the majority of 
the patients alive (n=67, 83.8%), allowing us to reliably evaluate prognostic factors for 
recurrence. According to these data, a 10-year follow-up would be reasonable to detect 
most recurrences, at least in high-risk patients. 
 
The disease-specific survival (DSS) rates were similar to those observed in other GCT 
series (Table 8). The 10-year survival was better for stage I patients than for patients with 
higher disease stages (II-III) (p=0.0170). If the tumor recurred, the mortality fro m GCT 
was 52.6%. The median time to die from GCT was 9.7 years (range 0.06 -33.9 years), and 
the median time to die after the first recurrence was 6.4 years (range 0.3-20.4 years). 
There was an increased risk of disease-specific death in tumors diagnosed before 1980 
(n=23, 28.8%) compared with tumors diagnosed after 1980 (n=57, 71.2%) (odds ratio; OR 
5.80, 95% CI 1.50-22.35, p=0.0107) (A. Färkkilä, unpublished data). As there were no 
differences in recurrence probabilities, this is most probably due to improvements in 
treatment modalities over the decades, most importantly, the introduction of platinum-
based chemotherapy in 1980. 
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Table 8. Disease-specific survival rates of 80 GCT patients according to time from 
diagnosis. 
 
Parameter DSS 
5 years 
     Stage I 
     Stage II-III 
97.5% 
98.6% 
88.9% 
10 years 
     Stage I 
     Stage II-III 
92.5% 
95.8% 
66.7% 
15 years 
     Stage I 
     Stage II-III 
91.3% 
94.4% 
66.7% 
If recurred* 47.4% 
           * mean follow-up time 16.8 years 
 
 
These data confirm that GCT usually presents with an indolent course of disease, with a 
mean survival of 13.5 years from diagnosis. However, 20-30% of the tumors recur and 
ultimately over 50% of the recurred patients die of GCT, with a mean survival of 7.8 years 
from the first recurrence. In view of these results, the major challenges in the treatment of 
GCT patients are identification of prognostic markers able to predict tumor recurrence and 
early detection and effective treatment of recurred disease.   
4.2 Prognostic factors for recurrence and survival of GCTs (IV) 
Molecular prognostic factors are needed for GCT, especially for stage I patients. We 
evaluated the protein expression profiles of the factors studied in the TTMA (Table 5) in 
relation to prognosis and survival. In summary, neither VEGF, its receptors, nor tumor 
MVD was associated with prognosis. AMHRII and its signaling cascade components were 
not associated with prognosis in GCTs, in contrast to findings in epithelial ovarian cancer 
(Bakkum-Gamez 2008). Of the EGF receptors, HER3 and HER4 were unrelated to 
prognosis, as was EGFR expression (N. Andersson, unpublished). Of the molecular 
prognostic factors, HER2 and GATA4 were associated with tumor recurrence (see Section 
4.2.1), and GATA4 was also associated with survival of GCT patients (see Section 4.2.2). 
 
Age at diagnosis, tumor mitotic index, histological subtype, and tumor size did not predict 
tumor recurrence or survival (II, IV). In univariate analysis, nuclear atypia was not 
associated with tumor recurrence (IV); however, in Kaplan-Meier analysis, high nuclear 
atypia was prognostic of shorter DFS (Figure 13 F) and DSS (Figure 14 E) (see Sections 
4.2.1 and 4.2.2). 
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Expression of the factors at mRNA level was not associated with prognosis. This is 
probably attributable to the relatively small number of primary tumors (n=28). Another 
factor contributing  to the lack of association of mRNA levels with recurrence is the short 
follow-up time; 50% (n=14) of the tumors were diagnosed after 2004, and 29% (n=8) 
were diagnosed after 2008. 
4.2.1 Prognostic factors for recurrence in GCTs 
HER2 is a known oncogene and its overexpression is associated with worse prognosis in 
various cancer types. We stained the TTMA for the expression of EGF receptors HER2, 
HER3, and HER4. The expressions are summarized in Table 5.  
  
HER3 and HER4 were readily expressed in GCTs (Table 5). We found positive 
expression of HER2 in 98% of the GCTs, while only 2% were either very low or negative 
for HER2. In 90% of the tumors, HER2 was also expressed in the phosphorylated form. 
This finding contradicts the studies reporting GCTs to be negative for HER2 (Kusamura 
2003; Leibl 2006; Mayr 2006; Menczer 2007). These mostly immunohistochemical 
studies have used various methods and antibodies. Some of them have applied the 
HercepTest®, which was originally developed for screening of breast cancer (Leibl 2006; 
Mayr 2006). In breast cancer, amplification of the HER2 gene leads to up to 100-fold 
overexpression of the oncoprotein (Press 1993). However, in GCTs the HER2 gene was 
rarely amplified ((Mayr 2006) and this study). This may lead to milder overexpression in 
GCTs, which might be undetectable by the HercepTest®. In support of this notion, we 
found relatively high levels of HER2 mRNA transcript in all 34 GCTs when analyzed 
with quantitative PCR (N. Andersson, unpublished data). Based on these results, HER2 
expression may be transcriptionally mediated in GCTs. This is in line with the findings in 
epithelial ovarian carcinomas, where HER2 protein overexpression was not as strongly 
associated with gene amplification as in breast cancer (Lassus 2004). Representative 
images of low and high expression groups of HER2 and GATA4 are presented in Figure 
12. 
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Figure 12. TTMA of 80 primary and 12 recurrent GCTs was stained for GATA4 (Anttonen 
2005) (A, B) and HER2 (C, D), and the tumors were divided into low and high 
expression groups (IV). 
 
The protein expressions of HER2 and GATA4 correlated positively (p=0.0006) in all 
tumors. Further, both high HER2 and high GATA4 expressions were associated with 
higher tumor stage (stages II-III and Ib-III; p<0.05). No correlations were found with the 
other clinicopathological parameters of Tables 2 and 7. 
 
In univariate analyses, high expression of HER2 and GATA4 was associated with tumor 
recurrence, even in stage Ia tumors (contingency tabling, data not shown). In Kaplan-
Meier analyses, high expression of HER2 (HR 3.15, 95% CI 1.20-8.00) (Figure 13 C) and 
high expression of GATA4 (HR 4.04, 95% CI 1.52-12.64) (Figure 13 D) were prognostic 
of shorter disease-free survival (DFS). The DFS was even shorter when the two factors 
were both highly expressed in the tumor (HR 6.61, 95%CI 1.98-25.44) (Figure 13 E). 
Both high GATA4 (stage-adjusted HR; AHR 3.96, 95% CI 1.45-12.57, p=0.006) and high 
HER2 (AHR 3.02, 95% CI 1.11-7.94, p=0.03) predicted DFS independently of tumor 
stage. However, in multivariate stage-adjusted analyses, GATA4 was superior to HER2 in 
predicting recurrence (Table 3 C in IV). 
 
According to these data, HER2 is expressed in the majority of GCTs, with high expression 
being associated with higher stage and increased recurrence risk. HER2 may thus be 
considered a target for treatment for the more aggressive GCTs, and as in breast cancer 
Low High 
GATA4 
HER2 
A B 
C D 
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(Slamon 2001) HER2 immunostaining could be used to select patients for targeted 
therapy.  In multivariate analyses, however, GATA4 seemed superior to HER2 in 
delineating the prognosis of CCT patients. Overall, keeping in mind the lack of HER2 
gene amplification in GCTs and the lack of HER2 overexpression with the clinically 
available test (HercepTest ®), the single analysis of HER2 expression is likely to be of 
limited use in the prognostic evaluation of GCT patients. However, combined with 
GATA4, HER2 may provide additional information on the biological behavior of GCTs. 
 
Nuclear atypia was prognostic of shorter DFS (HR 3.00, 95% CI 1.10-7.66) (Figure 13 F), 
and in Cox regression analyses high nuclear atypia was an independent prognostic factor 
for DFS (Table 9 A). However, after adjusting for stage, the AHR, its 95% CI, and p-value 
of nuclear atypia were not very different from those of GATA4 (Table 9 A). Moreover, 
the combined high expression of HER2 and GATA4 was an even stronger independent 
prognostic factor when analyzed with nuclear atypia (Table 9 B). High expression of both 
HER2 and GATA4 was an independent prognostic factor also when studied only in stage 
Ia (HR 11.5, 95% CI 1.76-79.41, p=0.0126) and stage I (HR 5.62, 95% CI 1.45-23.48, 
p=0.0146) tumors.  
 
Whether a tumor has high- or low-grade nuclear atypia is the subjective opinion of a 
pathologist, with great inter- and intra-observer variation. In this study, the same 
pathologist assigned the degree of nuclear atypia for all samples. In clinical pathology, this 
is rarely achievable and may complicate the use of nuclear atypia as a prognostic factor in 
GCTs. 
Table 9. Cox regression models for DFS with HER2, GATA4, and nuclear atypia (A) and 
combined expression of HER2 +GATA4 and nuclear atypia (B). HR: hazard ratio, 
AHR: stage-adjusted HR. 
 
Factor 
A 
Expression 
level 
HR 95% CI p AHR 95% CI p 
HER2 High 2.19 0.79-6.00 0.126 2.32 0.82-6.38 0.111 
GATA4 High 2.70 0.91-8.98 0.073 2.83 0.94-9.46 0.064 
Nuclear atypia High 2.81 1.01-7.38 0.048 2.91 1.04-7.72 0.043 
B        
HER2 + GATA4 High + High 6.30 1.85-24.59 0.003 8.75 2.20-39.48 0.002 
Nuclear atypia High 1.44 0.31-5.09 0.609 1.27 0.26-4.67 0.737 
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Figure 13. Kaplan-Meier curves for disease-free survival to the first recurrence of 80 GCT 
patients according to tumor stage (A, B), expression of HER2 (C), GATA4 (D), 
HER2 and GATA4 (E), and nuclear atypia (F) (IV). Log-rank test, *: significant 
difference at p<0.05, **: significant difference at p<0.01. The p-value in E was 
derived from comparison between the low+low and high+high groups. 
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4.2.2 Prognostic factors for survival in GCTs  
Next we analyzed the factors affecting survival in GCTs. We found that patients with 
stage II-III tumors had shorter DSS (Figure 14 A), although one must bear in mind that the 
number of stage II-III patients was relatively small (n=9). The DSS was not different in 
stage Ia patients compared with stage Ib-III patients (Figure 14 B). HER2 expression was 
not associated with survival (Figure 14 C). High GATA4 expression was prognostic of 
shorter DSS; in Kaplan-Meier estimates, the 10-year DSSs were 84.2% (SE 6.2%) for 
high GATA4 and 97.8% (SE 2.2%) for low GATA4 expression (p=0.0383) (Figure 14 D). 
High nuclear atypia was also prognostic of DSS, and the 10-year survival rates were 
76.3% (SE 10.4%) for high nuclear atypia and 96.4% (SE 2.5%) for low nuclear atypia 
(p=0.0155) (Figure 14 E). In multivariate analyses, stage II-III and high nuclear atypia 
were both independently prognostic of worse DSS (IV: Table 3 D). In stage I and stage Ia 
tumors, both GATA4 and nuclear atypia were prognostic to shorter DSS (Table 10).  
Table 10. GATA4 and nuclear atypia as prognostic factors for DSS in stage I and stage Ia 
GCTs (IV). 
 
Factor Stage I   HR (95% CI) p-value Stage Ia   HR (95% CI), p-value 
GATA4   4.99 (1.14-34.21), 0.0322 7.71 (1.12-151.85), 0.0375 
Nuclear atypia  5.29 (1.16-26.94), 0.0319 18.2 (2.32-369.6), 0.0062 
 
 
Based on these results, nuclear atypia seemed to be the most potent factor in delineating 
disease-specific survival of GCT patients. However, one must keep in mind that the 
number of GCT-related deaths was relatively small in this study (n=11).  
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Figure 14. Kaplan-Meier curves for disease-specific survival of 80 GCT patients according to 
tumor stage (A, B), expression of HER2 (C), GATA4 (D), and nuclear atypia (E) 
(IV). Log-rank test, *: significant difference at p < 0.05 **: significant difference 
at p < 0.01.  
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4.3 Role of GATA4 in GCTs 
According to this study, GATA4 is an important factor in delineating the prognosis of 
GCT patients; high expression of GATA4 was prognostic of increased risk of recurrences 
and unfavorable survival. Keeping in mind the essential role of GATA4 in normal 
granulosa cell function, GATA4 potentially has a crucial role in GCT pathogenesis.  
 
In breast cancer, GATA4 expression positively correlated with HER2 expression (Bertucci 
2004), and GATA4 was shown to directly regulate HER2 expression by binding HER2 
promoter (Hua 2009). In GCTs, we found that the expressions of GATA4 and HER2 
colocalized in immunohistochemistry, together delineating an aggressive subset of GCTs. 
However, overexpression of GATA4 was more strongly associated with shorter DFS, and 
may thus be one of the transcription factors contributing to HER2 protein overexpression 
in the aggressive GCTs. 
 
GATA4 is also likely to contribute to other factors in this study. AMH is a known target 
gene of GATA4, and in granulosa cells GATA4 directly upregulates AMH expression by 
binding to its promoter (Tremblay 2001a; Anttonen 2003). This may well be one of the 
mechanisms by which AMH expression is regulated in GCT tumorigenesis. However, 
based on these studies, the most aggressive tumor-promoting conditions involve increased 
GATA4 and decreased AMH expression. The expressions of GATA4 and AMH did not 
correlate in the TTMA (Anttonen 2005). The regulatory role of GATA4 in GCT 
pathogenesis is likely to involve cofactors that interact with GATA4 in AMH regulation 
such as SF-1 and friend of GATA-2 (FOG-2) (Tremblay 1999; Tremblay 2001b; Anttonen 
2003). GATA4 may also have a dual role in regulating the same target gene expression 
depending on the interplay with different cofactors (Tremblay 2001c; Anttonen 2003).  
 
In granulosa cells, GATA4 was required for TGF-b signaling through interaction with 
Smad3 (Anttonen 2006), and in GCTs GATA4 has been found to interact with FOXL2 
and Smad3  (M. Anttonen, unpublished data). This links GATA4 to the fundamental 
genetic and signaling cascade changes that may give rise to GCT. Further, GATA4 is 
directly involved in GCT cell survival, protecting GCT cells from apoptosis (Kyronlahti 
2008; Kyronlahti 2010). Moreover, GATA4 may also contribute to tumor angiogenesis in 
GCTs, as it was shown to bind VEGF promoter and act as a pro-angiogenic factor through 
VEGF in cardiac cells (Heineke 2007). 
 
Based on this study and the current literature, GATA4 is likely to be a major pathogenetic 
factor in GCTs. GATA4 is also fundamentally involved in delineating the recurrences and 
survival of GCT patients. Immunostaining of GATA4 is likely to be useful in prognostic 
evaluation of GCTs. Currently, there are no known therapies that target GATA4. 
Transcription factors are difficult to target in cancer therapy due to their ubiquitous 
expression and important functions in normal tissues. Therefore, the development of 
GATA4-targeted therapies is likely to involve the GATA4 target genes. In view of our 
results on GCTs, the most potential GATA4-linked targets for treatment include AMH, 
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AMHRII, and other members of the TGF-β signaling pathway, VEGF, VEGFR2, and 
HER2. 
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Conclusions and future perspectives 
1. AMH, its receptor AMHRII, and its signaling cascade components were expressed and 
active in GCTs. Treatment with rhAMH induced apoptosis in GCT cells. AMH is likely to 
play an important role in GCT pathogenesis by acting as a growth inhibitor, and AMH and 
AMHRII are new potential targets for anti-cancer treatment of advanced or recurred 
GCTs. 
 
2. VEGF and its receptor VEGFR-2 were highly expressed in GCTs. GCTs produced 
significant amounts of soluble VEGF and expressed VEGFR-2 in an active, 
phosphorylated form. Further, the inhibition of endogenous VEGF led to a decrease in 
VEGFR-2 activation and to a significant increase in apoptosis in GCT cells. The results 
suggest that VEGF acts auto- or paracrinely to promote tumor growth in GCTs. VEGF-
targeted treatments are potential treatment options for aggressive GCTs. 
 
3. GATA4 is an important factor in delineating the prognosis and survival of GCT patients 
and may be useful in the clinicopathological assessment of GCT prognosis. Members of 
the EGF receptor family are expressed in GCTs and are potential targets for therapy.  
 
This study demonstrates that several granulosa cell growth factors play significant roles in 
GCT pathogenesis and describes potential targets for biological treatment of poor-
prognosis GCT patients. Targeting the receptors of the growth factors, such as AMH, 
VEGF, or EGF, is an attractive option in cancer therapy, especially with high and 
preferably cancer-specific expression of the receptor. Of these, AMHRII has been shown 
to be a potential cancer-specific molecule that may be targeted in gynecological cancers 
with, for instance, immunotherapy.  
 
Modern, extremely efficient, high throughput technologies allow the screening of 
hundreds of cancer drugs for tumor-specific responses (Iljin 2009), opening up the 
possibilities to personalize cancer treatments. This is important, especially in rare tumors, 
such as GCT, where evidence-based data on the efficacy of different regimens from large 
clinical trials are difficult to obtain. More detailed genetic and proteomic analyses of 
GCTs would build a basis for the detection of new cancer/GCT-specific molecular and 
signaling pathways that can be utilized in the search for prognostic factors or treatment 
options. These studies would also shed further light on the mechanism of how molecular 
changes, especially FOXL2 mutation, contribute to GCT pathogenesis.  
 
The detailed analysis of our internally large clinical series of over 230 GCT patients 
allows us to review also the clinical risk factors for recurrences and survival. Analysis of 
the large clinical cohort will give new information to clinicians and patients on the 
characteristics of this disease. In addition, with the prospective study started in 2007, we 
have collected serum samples for the development of better serum markers for GCT, such 
as AMH. The results of these studies will putatively lead to more reliable detection of 
GCT recurrence and directly improve the follow-up of GCT patients. These analyses 
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facilitate the development of clinical guidelines for evidence-based treatment, prognostic 
evaluation, and follow-up of GCT patients. 
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